ATE414768T1 - Bibliotheken heterodimerer rezeptoren mittels phagemiden - Google Patents

Bibliotheken heterodimerer rezeptoren mittels phagemiden

Info

Publication number: ATE414768T1
Authority: AT; Austria
Prior art keywords: domain; terminal; libraries; polypeptide; sequences
Prior art date: 1991-04-10

Application number

AT04076718T

Other languages

English (en)

Inventor

Angray Kang

Carlos Barbas

Richard A Lerner

Original Assignee

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-04-10

Filing date

1992-04-10

Publication date

2008-12-15

1992-04-10 Application filed by Scripps Research Inst filed Critical Scripps Research Inst

2008-12-15 Application granted granted Critical

2008-12-15 Publication of ATE414768T1 publication Critical patent/ATE414768T1/de

Links

239000000833 heterodimer Substances 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
241000724791 Filamentous phage Species 0.000 abstract 4
108700005091 Immunoglobulin Genes Proteins 0.000 abstract 2
239000003446 ligand Substances 0.000 abstract 2
239000002773 nucleotide Substances 0.000 abstract 2
125000003729 nucleotide group Chemical group 0.000 abstract 2
240000004307 Citrus medica Species 0.000 abstract 1
108020004414 DNA Proteins 0.000 abstract 1
108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
108091034117 Oligonucleotide Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
210000004899 c-terminal region Anatomy 0.000 abstract 1
230000004927 fusion Effects 0.000 abstract 1
239000002245 particle Substances 0.000 abstract 1
230000028327 secretion Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Crystallography & Structural Chemistry (AREA)
Virology (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)

AT04076718T 1991-04-10 1992-04-10 Bibliotheken heterodimerer rezeptoren mittels phagemiden ATE414768T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US68360291A	1991-04-10	1991-04-10
US82662392A	1992-01-27	1992-01-27

Publications (1)

Publication Number	Publication Date
ATE414768T1 true ATE414768T1 (de)	2008-12-15

Family

ID=27103149

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT04076718T ATE414768T1 (de)	1991-04-10	1992-04-10	Bibliotheken heterodimerer rezeptoren mittels phagemiden
AT92910558T ATE269401T1 (de)	1991-04-10	1992-04-10	Bibliotheken heterodimerer rezeptoren mittels phagemiden

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT92910558T ATE269401T1 (de)	1991-04-10	1992-04-10	Bibliotheken heterodimerer rezeptoren mittels phagemiden

Country Status (14)

Country	Link
US (6)	US5658727A (de)
EP (2)	EP0580737B1 (de)
JP (4)	JP3672306B2 (de)
AT (2)	ATE414768T1 (de)
AU (1)	AU662148B2 (de)
CA (1)	CA2108147C (de)
DE (2)	DE69233750D1 (de)
DK (2)	DK0580737T3 (de)
ES (2)	ES2315612T3 (de)
FI (1)	FI120309B (de)
IE (1)	IE921169A1 (de)
NO (1)	NO319371B1 (de)
PT (1)	PT100379B (de)
WO (1)	WO1992018619A1 (de)

Families Citing this family (1329)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5427908A (en) *	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
US7063943B1 (en)	1990-07-10	2006-06-20	Cambridge Antibody Technology	Methods for producing members of specific binding pairs
US6916605B1 (en)	1990-07-10	2005-07-12	Medical Research Council	Methods for producing members of specific binding pairs
GB9206318D0 (en) *	1992-03-24	1992-05-06	Cambridge Antibody Tech	Binding substances
GB9015198D0 (en) *	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
DE69129154T2 (de) *	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE414768T1 (de) *	1991-04-10	2008-12-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
US5858657A (en) *	1992-05-15	1999-01-12	Medical Research Council	Methods for producing members of specific binding pairs
US5962255A (en) *	1992-03-24	1999-10-05	Cambridge Antibody Technology Limited	Methods for producing recombinant vectors
US6492160B1 (en)	1991-05-15	2002-12-10	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5871907A (en)	1991-05-15	1999-02-16	Medical Research Council	Methods for producing members of specific binding pairs
US6225447B1 (en)	1991-05-15	2001-05-01	Cambridge Antibody Technology Ltd.	Methods for producing members of specific binding pairs
US5270170A (en) *	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
US5733731A (en) *	1991-10-16	1998-03-31	Affymax Technologies N.V.	Peptide library and screening method
ES2341666T3 (es)	1991-12-02	2010-06-24	Medimmune Limited	Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US7067284B1 (en) *	1992-01-27	2006-06-27	The Scripps Research Institute	Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5733743A (en) *	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
CA2177988A1 (en)	1993-12-03	1995-06-08	Kazuo Higuchi	Expression vector for preparing an anti-body-variable-region library
DE69531148T2 (de) *	1994-01-31	2004-04-29	Trustees Of Boston University, Boston	Bibliotheken aus polyklonalen antikörpern
US20060078561A1 (en) *	1994-01-31	2006-04-13	The Trustees Of Boston University	Polyclonal antibody libraries
US6576236B1 (en)	1994-07-01	2003-06-10	Dana Farber Cancer Institute	Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US7597886B2 (en)	1994-11-07	2009-10-06	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US7820798B2 (en) *	1994-11-07	2010-10-26	Human Genome Sciences, Inc.	Tumor necrosis factor-gamma
US6326155B1 (en) *	1995-03-20	2001-12-04	Dyax Corp.	Engineering affinity ligands for macromolecules
US7429646B1 (en)	1995-06-05	2008-09-30	Human Genome Sciences, Inc.	Antibodies to human tumor necrosis factor receptor-like 2
US5702892A (en) *	1995-05-09	1997-12-30	The United States Of America As Represented By The Department Of Health And Human Services	Phage-display of immunoglobulin heavy chain libraries
US6475806B1 (en) *	1995-06-07	2002-11-05	Praecis Pharmaceuticals, Inc.	Anchor libraries and identification of peptide binding sequences
US7368111B2 (en)	1995-10-06	2008-05-06	Cambridge Antibody Technology Limited	Human antibodies specific for TGFβ2
US6090382A (en)	1996-02-09	2000-07-18	Basf Aktiengesellschaft	Human antibodies that bind human TNFα
US6537776B1 (en) *	1999-06-14	2003-03-25	Diversa Corporation	Synthetic ligation reassembly in directed evolution
US20030219752A1 (en) *	1995-12-07	2003-11-27	Diversa Corporation	Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6939689B2 (en)	1995-12-07	2005-09-06	Diversa Corporation	Exonuclease-mediated nucleic acid reassembly in directed evolution
US6713279B1 (en)	1995-12-07	2004-03-30	Diversa Corporation	Non-stochastic generation of genetic vaccines and enzymes
US6764835B2 (en)	1995-12-07	2004-07-20	Diversa Corporation	Saturation mutageneis in directed evolution
US6358709B1 (en)	1995-12-07	2002-03-19	Diversa Corporation	End selection in directed evolution
US6740506B2 (en)	1995-12-07	2004-05-25	Diversa Corporation	End selection in directed evolution
US5830696A (en)	1996-12-05	1998-11-03	Diversa Corporation	Directed evolution of thermophilic enzymes
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
DE19629143A1 (de) *	1996-07-19	1998-01-22	Bayer Ag	Vorrichtung zum Separieren von Mikroobjekten
US5985543A (en) *	1996-10-11	1999-11-16	The Trustees Of The University Of Pennsylvania	Compositions and methods for detection of antibody binding to cells
US5876925A (en) *	1996-10-11	1999-03-02	The Trustees Of The University Of Pennsylvania	Magnetically activated cell sorting for production of proteins
IL119587A (en) *	1996-11-07	2000-12-06	Univ Ramot	Method of preparing and for obtaining bimolecular interactions
US5817497A (en) *	1996-11-26	1998-10-06	Incyte Pharmaceuticals	Glutathione s-transferase
AU6685698A (en) *	1997-03-07	1998-09-22	Sunol Molecular Corporation	Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
JP2002514919A (ja) *	1997-04-04	2002-05-21	バイオサイトダイアグノスティックス，インコーポレイテッド	多価ライブラリーおよびポリクローナルライブラリー
US6057098A (en) *	1997-04-04	2000-05-02	Biosite Diagnostics, Inc.	Polyvalent display libraries
US6555310B1 (en) *	1997-04-04	2003-04-29	Biosite Diagnostics, Inc.	Polyclonal libraries
PT1787999E (pt) *	1997-04-07	2010-11-11	Genentech Inc	Anticorpos anti-vegf
CN100480269C (zh)	1997-04-07	2009-04-22	基因技术股份有限公司	抗-血管内皮生长因子的抗体
US7365166B2 (en)	1997-04-07	2008-04-29	Genentech, Inc.	Anti-VEGF antibodies
ATE505543T1 (de)	1997-04-16	2011-04-15	Millennium Pharm Inc	Zusammensetzung, umfassend einen antikörper, der selektiv an ein cysteinreiches sekretiertes protein (crsp) bindet
NZ516848A (en)	1997-06-20	2004-03-26	Ciphergen Biosystems Inc	Retentate chromatography apparatus with applications in biology and medicine
PT1032660E (pt) *	1997-11-17	2009-12-28	Micromet Ag	Processo de identificação dos domínios do sítio de ligação que retêm a capacidade de ligação a um epítope
WO1999031265A1 (en) *	1997-12-12	1999-06-24	Way Jeffrey C	Compounds and methods for the inhibition of protein-protein interactions
US7390619B1 (en)	1998-02-11	2008-06-24	Maxygen, Inc.	Optimization of immunomodulatory properties of genetic vaccines
DE69943022D1 (de)	1998-03-19	2011-01-20	Human Genome Sciences Rockville	Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US6344330B1 (en) *	1998-03-27	2002-02-05	The Regents Of The University Of California	Pharmacophore recombination for the identification of small molecule drug lead compounds
US7056517B2 (en)	1998-04-13	2006-06-06	The Forsyth Institute	Glucosyltransferase immunogens
US7163682B2 (en)	1998-04-13	2007-01-16	The Forsyth Institute	Glucan binding protein and glucosyltransferase immunogens
EP1096955B9 (de)	1998-07-13	2006-07-05	Board of Regents, The University of Texas System	Verwendung von antikörper gegen aminophospholipide zur krebsbehandlung
EP1100890A2 (de)	1998-07-27	2001-05-23	Genentech, Inc.	Verbesserung der transformationseffizienz in phagendisplay durch abänderung des hüllproteins
US6190908B1 (en) *	1998-08-12	2001-02-20	The Scripps Research Institute	Modulation of polypeptide display on modified filamentous phage
US6420110B1 (en)	1998-10-19	2002-07-16	Gpc Biotech, Inc.	Methods and reagents for isolating biologically active peptides
IL127127A0 (en) *	1998-11-18	1999-09-22	Peptor Ltd	Small functional units of antibody heavy chain variable regions
US20090130718A1 (en) *	1999-02-04	2009-05-21	Diversa Corporation	Gene site saturation mutagenesis
EP2301947A3 (de)	1999-02-26	2011-11-23	Millennium Pharmaceuticals, Inc.	Sekretierte Proteine und Verwendungen dafür
CA2363779A1 (en)	1999-02-26	2000-08-31	Human Genome Sciences, Inc.	Human endokine alpha and methods of use
NZ592550A (en)	1999-03-25	2012-12-21	Abbott Gmbh & Co Kg	Compostion comprising antibody capable of binding to p40 subunit of IL-12
DE19915057A1 (de)	1999-04-01	2000-10-19	Forschungszentrum Borstel	Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
US6492497B1 (en)	1999-04-30	2002-12-10	Cambridge Antibody Technology Limited	Specific binding members for TGFbeta1
PT2067788E (pt) *	1999-05-18	2015-10-29	Dyax Corp	Bibliotecas de fragmentos fab e métodos para a sua utilização
US20020102613A1 (en) *	1999-05-18	2002-08-01	Hoogenboom Hendricus Renerus Jacobus Mattheus	Novel Fab fragment libraries and methods for their use
US7291714B1 (en)	1999-06-30	2007-11-06	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
US20040001826A1 (en) *	1999-06-30	2004-01-01	Millennium Pharmaceuticals, Inc.	Glycoprotein VI and uses thereof
HU228477B1 (en)	1999-08-23	2013-03-28	Dana Farber Cancer Inst Inc	Pd-1, a receptor for b7-4, and uses therefor
US6673346B1 (en)	1999-08-31	2004-01-06	The Regents Of The University Of Michigan	Compositions and methods for the treatment of sepsis
US20070111259A1 (en) *	1999-10-02	2007-05-17	Medarex, Inc.	Human antibodies
US7135287B1 (en)	1999-10-02	2006-11-14	Biosite, Inc.	Human antibodies
US6794132B2 (en)	1999-10-02	2004-09-21	Biosite, Inc.	Human antibodies
US6680209B1 (en)	1999-12-06	2004-01-20	Biosite, Incorporated	Human antibodies as diagnostic reagents
JP2003516755A (ja) *	1999-12-15	2003-05-20	ジェネンテック・インコーポレーテッド	ショットガン走査、すなわち機能性タンパク質エピトープをマッピングするための組み合わせ方法
AU784883B2 (en)	1999-12-30	2006-07-20	President And Fellows Of Harvard College	Methods and compositions relating to modulation of hepatocyte growth, plasma cell differentiation or T cell subset activity by modulation of XBP-1 activity
AU2001236807A1 (en)	2000-02-10	2001-08-20	Abbott Laboratories	Antibodies that bind human interleukin-18 and methods of making and using
US7700735B2 (en) *	2000-03-01	2010-04-20	Medimmune, Llc	High potency recombinant antibodies and method for producing them
ES2529300T3 (es)	2000-04-12	2015-02-18	Novozymes Biopharma Dk A/S	Proteínas de fusión de albúmina
DK1276855T3 (da) *	2000-04-17	2012-11-26	Dyax Corp	Fremgangsmåde til konstruktion af visningsbiblioteker over genetiske pakker for medlemmer af en diversificeret peptidfamilie
US8288322B2 (en)	2000-04-17	2012-10-16	Dyax Corp.	Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
US7495070B2 (en) *	2000-04-24	2009-02-24	Yale University	Protein binding miniature proteins
US7297762B2 (en) *	2000-04-24	2007-11-20	Yale University	Modified avian pancreatic polypeptide miniature binding proteins
EP1714661A3 (de)	2000-05-19	2012-03-14	The Center for Blood Research, INC.	Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
US20030031675A1 (en)	2000-06-06	2003-02-13	Mikesell Glen E.	B7-related nucleic acids and polypeptides useful for immunomodulation
CN1443074A (zh)	2000-06-08	2003-09-17	血液研究中心	抑制免疫球蛋白介导的再灌注损伤的方法和组合物
AU2001282856A1 (en)	2000-06-15	2001-12-24	Human Genome Sciences, Inc.	Human tumor necrosis factor delta and epsilon
KR20120053525A (ko)	2000-06-16	2012-05-25	캠브리지 안티바디 테크놀로지 리미티드	면역특이적으로 ＢＬｙＳ에 결합하는 항체
AU7309601A (en)	2000-06-28	2002-01-08	Genetics Inst	Pd-l2 molecules: novel pd-1 ligands and uses therefor
AU2001277648A1 (en)	2000-07-14	2002-04-15	Cropdesign N.V.	Plant cyclin-dependent kinase inhibitors
UA81743C2 (uk)	2000-08-07	2008-02-11	Центокор, Инк.	МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US7288390B2 (en)	2000-08-07	2007-10-30	Centocor, Inc.	Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en)	2000-08-07	2005-06-07	Centocor, Inc.	Anti-IL-12 antibodies and compositions thereof
GB0022978D0 (en)	2000-09-19	2000-11-01	Oxford Glycosciences Uk Ltd	Detection of peptides
WO2002046208A2 (en)	2000-11-01	2002-06-13	Elusys Therapeutics, Inc.	Method of producing biospecific molecules by protein trans-splicing
PL362606A1 (pl)	2000-11-28	2004-11-02	Wyeth	Analiza ekspresji kwasów nukleinowych KIAA i polipeptydów KIAA użytecznych w diagnozowaniu i leczeniu raka prostaty
MXPA03004688A (es)	2000-11-28	2003-09-05	Wyeth Corp	Analisis de expresion de acidos nucleicos y polipeptidos fkbp utiles en diagnostico.
JP4434580B2 (ja)	2000-11-28	2010-03-17	メディミューン，エルエルシー	予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法
AU2002225914A1 (en) *	2000-12-08	2002-06-18	Alexion Pharmaceuticals, Inc.	Plasmid vectors
DE60143544D1 (de)	2000-12-12	2011-01-05	Medimmune Llc	Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US6979556B2 (en) *	2000-12-14	2005-12-27	Genentech, Inc.	Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
ATE498718T1 (de)	2000-12-18	2011-03-15	Dyax Corp	Gerichtete bibliotheken die genetisch verpackt sind
ATE328874T1 (de) *	2000-12-22	2006-06-15	Ortho Mcneil Pharm Inc	Substituieten triazoldiamin derivaten und ihre verwendung als kinase inhibitoren
JP4986370B2 (ja)	2000-12-22	2012-07-25	マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ	Ｒｇｍおよびそのモジュレーターの用途
EA012079B3 (ru)	2001-01-05	2018-07-31	Пфайзер Инк.	Моноклональное антитело к рецептору инсулиноподобного фактора роста i (igf-i) и способы его применения
CA2437811A1 (en)	2001-02-09	2002-08-22	Human Genome Sciences, Inc.	Human g-protein chemokine receptor (ccr5) hdgnr10
EP2316276A3 (de)	2001-02-23	2011-08-03	DSM IP Assets B.V.	Genes qui codant pour l'enzymes proteolytiques derivees de aspargilli
AU2002322478A1 (en) *	2001-03-02	2002-12-16	Medimmune, Inc.	Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
CA2439263C (en)	2001-03-02	2012-10-23	Frank Becker	Three hybrid assay system
CA2342376C (en) *	2001-03-20	2013-11-12	Marco Colonna	A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20090081199A1 (en) *	2001-03-20	2009-03-26	Bioxell S.P.A.	Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en)	2001-03-20	2012-07-31	Cosmo Research & Development S.P.A.	Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en)	2001-03-20	2015-03-17	Novo Nordisk A/S	Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
WO2002076196A1 (en)	2001-03-22	2002-10-03	Abbott Gmbh & Co. Kg	Transgenic animals expressing antibodies specific for genes of interest and uses thereof
EP2388590A1 (de)	2001-04-02	2011-11-23	Dana Farber Cancer Institute	PD-1, ein Rezeptor für B7-4, und Verwendungen dafür
EP1385864B1 (de)	2001-04-13	2010-06-09	Human Genome Sciences, Inc.	Anti-VEGF-2 Antikörper
EP2258718A1 (de)	2001-04-16	2010-12-08	Wyeth Holdings Corporation	Polypeptidantigene codierende offene Leseraster aus Streptococcus Pneumoniae und Verwendungen davon
AU2002305246B2 (en)	2001-04-27	2006-06-08	Alexion Pharmaceuticals, Inc.	Phagemid vectors
KR100942393B1 (ko)	2001-05-25	2010-02-17	휴먼 게놈 사이언시즈, 인코포레이티드	Ｔｒａｉｌ 수용체에 면역특이적으로 결합하는 항체
WO2002098280A2 (en)	2001-06-04	2002-12-12	Ikonisys Inc.	Method for detecting infectious agents using computer controlled automated image analysis
CA2385745C (en)	2001-06-08	2015-02-17	Abbott Laboratories (Bermuda) Ltd.	Methods of administering anti-tnf.alpha. antibodies
US20040002058A1 (en) *	2001-06-21	2004-01-01	Uab Research Foundation	Chimeric capsid proteins and uses thereof
EP1409551A4 (de) *	2001-06-21	2004-10-13	Uab Research Foundation	Chimere kapsidproteine und deren verwendung
EP2270188A3 (de)	2001-06-22	2011-09-07	Pioneer Hi-Bred International, Inc.	Defensinpolynucleotide und Verfahren zu ihrer Verwendung
WO2003004604A2 (en) *	2001-07-06	2003-01-16	Genentech, Inc.	Phage displayed pdz domain ligands
US6867189B2 (en)	2001-07-26	2005-03-15	Genset S.A.	Use of adipsin/complement factor D in the treatment of metabolic related disorders
DE60224291T2 (de) *	2001-08-27	2008-12-11	Genentech, Inc., South San Francisco	System zur antikörperexpression und- synthese
AU2002347404A1 (en) *	2001-09-14	2003-04-01	Cytos Biotechnology Ag	In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US20040142325A1 (en)	2001-09-14	2004-07-22	Liat Mintz	Methods and systems for annotating biomolecular sequences
CA2460639C (en) *	2001-09-19	2013-07-16	Alexion Pharmaceuticals, Inc.	Engineered templates and their use in single primer amplification
US7414111B2 (en) *	2001-09-19	2008-08-19	Alexion Pharmaceuticals, Inc.	Engineered templates and their use in single primer amplification
JP4578098B2 (ja)	2001-10-01	2010-11-10	ダイアックス、コープ	多重鎖真核ディスプレイベクターとその使用
WO2003035842A2 (en) *	2001-10-24	2003-05-01	Dyax Corporation	Hybridization control of sequence variation
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
KR100450864B1 (ko) *	2001-11-23	2004-10-01	한국과학기술연구원	Ｒｎａ 표적 분자에 대해 특이성이 향상된네오마이신-클로람페니콜 헤테로 이합체 및 그의 제조방법
WO2003051917A2 (en)	2001-12-18	2003-06-26	Endocube Sas	Novel death associated proteins of the thap family and related par4 pathways involved in apoptosis control
US7858297B2 (en)	2001-12-18	2010-12-28	Centre National De La Recherche Scientifique Cnrs	Chemokine-binding protein and methods of use
WO2003054155A2 (en)	2001-12-19	2003-07-03	Bristol-Myers Squibb Company	Pichia pastoris formate dehydrogenase and uses therefor
ES2425738T3 (es)	2001-12-21	2013-10-17	Human Genome Sciences, Inc.	Proteínas de fusión de la albúmina
US20040009498A1 (en) *	2002-01-14	2004-01-15	Diversa Corporation	Chimeric antigen binding molecules and methods for making and using them
JP2005523688A (ja) *	2002-01-18	2005-08-11	ブリストル−マイヤーズ　スクイブ　カンパニー	タンパク質チロシンキナーゼおよび／またはタンパク質チロシンキナーゼ経路と相互作用する化合物の活性を予測するためのポリヌクレオチドおよびポリペプチドの同定
US7094579B2 (en)	2002-02-13	2006-08-22	Xoma Technology Ltd.	Eukaryotic signal sequences for prokaryotic expression
US20030166010A1 (en) *	2002-02-25	2003-09-04	Affholter Joseph A.	Custom ligand design for biomolecular filtration and purification for bioseperation
WO2003073910A2 (en) *	2002-03-01	2003-09-12	Bayer Corporation	Assays for cancer patient monitoring based on levels of analyte components of the plasminogen activator system in body fluid samples
ATE441107T1 (de)	2002-03-01	2009-09-15	Siemens Healthcare Diagnostics	Assays zur überwachung von krebspatienten auf grundlage der spiegel des analyten für die extrazelluläre domäne (ecd) des epidermalen wachstumsfaktor-rezeptors (egfr), allein oder in kombination mit anderen analyten, in proben von kírperflüssigkeiten
AU2003217976A1 (en)	2002-03-07	2003-09-22	The Forsyth Institute	Immunogenicity of glucan binding protein
EP1497445A2 (de) *	2002-04-01	2005-01-19	Human Genome Sciences, Inc.	Spezifisch an gmad bindende antikörper
GB0207533D0 (en)	2002-04-02	2002-05-08	Oxford Glycosciences Uk Ltd	Protein
US7745192B2 (en)	2002-04-03	2010-06-29	Venomics Pty Limited	Prothrombin activating protein
AU2003226065B2 (en)	2002-04-12	2009-02-26	Ludwig Institute For Cancer Research, Ltd	Recombinant anti-interleukin-9 antibodies
US20030206898A1 (en)	2002-04-26	2003-11-06	Steven Fischkoff	Use of anti-TNFalpha antibodies and another drug
PT1506291E (pt)	2002-05-21	2010-09-21	Dsm Ip Assets Bv	Novas fosfolipases e suas utilizações
CA2488441C (en) *	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
EP2305710A3 (de)	2002-06-03	2013-05-29	Genentech, Inc.	Synthetische Antikörperphagenbibliotheken
EP2070949B1 (de) *	2002-06-10	2013-01-16	Vaccinex, Inc.	C35-Antikörper und ihre Verwendung zur Behandlung von Krebs
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
WO2003106639A2 (en) *	2002-06-14	2003-12-24	Dyax Corporation	Recombination of nucleic acid library members
CA2491310C (en)	2002-07-15	2015-10-06	Board Of Regents, The University Of Texas System	Compositions comprising cell-impermeant duramycin derivatives
USRE47770E1 (en)	2002-07-18	2019-12-17	Merus N.V.	Recombinant production of mixtures of antibodies
ES2442615T5 (es)	2002-07-18	2023-03-16	Merus Nv	Producción recombinante de mezclas de anticuerpos
CN101745112A (zh)	2002-07-19	2010-06-23	艾博特生物技术有限公司	TNFα相关疾病的治疗
US7250551B2 (en)	2002-07-24	2007-07-31	President And Fellows Of Harvard College	Transgenic mice expressing inducible human p25
ES2346868T3 (es)	2002-08-10	2010-10-21	Yale University	Antagonistas de receptor nogo.
US20040067532A1 (en)	2002-08-12	2004-04-08	Genetastix Corporation	High throughput generation and affinity maturation of humanized antibody
DK1534335T4 (en)	2002-08-14	2015-10-05	Macrogenics Inc	FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2004018660A2 (en)	2002-08-19	2004-03-04	Dsm Ip Assets B.V.	Novel lipases and uses thereof
KR20050058407A (ko)	2002-08-20	2005-06-16	밀레니엄 파머슈티컬스 인코퍼레이티드	자궁경부암의 확인, 평가, 예방 및 요법을 위한 조성물, 키트 및 방법
US7455989B2 (en)	2002-08-20	2008-11-25	Yeda Research And Development Co. Ltd.	AKAP84 and its use for visualization of biological structures
WO2004030613A2 (en)	2002-09-04	2004-04-15	University Of Louisville Research Foundation, Inc.	Cancer therapy using beta glucan and antibodies
EP1539234A4 (de) *	2002-09-05	2006-02-15	Medimmune Inc	Verfahren zur prävention oder behandlung von zellmalignität durch verabreichung von cd2-antagonisten
ES2301818T3 (es) *	2002-09-18	2008-07-01	The Trustees Of The University Of Pennsylvania	Composiciones, procedimientos y kits para la deteccion de un antigeno sobre una celula y en una mezcla bilogica.
ATE502051T1 (de)	2002-10-16	2011-04-15	Purdue Pharma Lp	Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
US20060134100A1 (en) *	2002-11-05	2006-06-22	Ali Amara	Dc-sign blockers and their use for preventing or treating viral infections
US7427469B2 (en) *	2002-11-05	2008-09-23	Institut Pasteur	Method of treating cytomegalovirus with DC-SIGN blockers
AU2003287622A1 (en) *	2002-11-06	2004-06-03	Fraunhofer Usa	Expression of foreign sequences in plants using trans-activation system
US7683238B2 (en) *	2002-11-12	2010-03-23	iBio, Inc. and Fraunhofer USA, Inc.	Production of pharmaceutically active proteins in sprouted seedlings
US7692063B2 (en) *	2002-11-12	2010-04-06	Ibio, Inc.	Production of foreign nucleic acids and polypeptides in sprout systems
WO2004048543A2 (en) *	2002-11-26	2004-06-10	Dyax Corporation	Methods and compositions for controlling valency of phage display
DE10256669B4 (de) *	2002-12-04	2006-03-09	Universitätsklinikum Charité an der Humboldt-Universität zu Berlin Technologietransferstelle	Gemisch mindestens zweier Fusionsproteine sowie ihre Herstellung und Verwendung
WO2004063337A2 (en) *	2003-01-07	2004-07-29	Dyax Corporation	Kunitz domain library
WO2004065416A2 (en) *	2003-01-16	2004-08-05	Genentech, Inc.	Synthetic antibody phage libraries
AU2004206250B8 (en) *	2003-01-21	2009-09-17	Bristol-Myers Squibb Company	Polynucleotide encoding a novel acyl coenzyme a, monoacylglycerol acyltransferase-3 (MGAT3), and uses thereof
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004070016A2 (en)	2003-02-03	2004-08-19	Fraunhofer Usa Inc.	System for expression of genes in plants
EP1947116B1 (de)	2003-02-10	2017-06-21	2-BBB Medicines B.V.	Differenziell exprimierte Nukleinsäuren der Blut-Hirnschranke bei einer Entzündung
WO2004073656A2 (en)	2003-02-20	2004-09-02	Seattle Genetics, Inc.	Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US20040180387A1 (en)	2003-03-13	2004-09-16	Fujirebio Diagnostics, Inc.	Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
GEP20094629B (en)	2003-03-19	2009-03-10	Biogen Idec Inc	Nogo receptor binding protein
US7294701B2 (en) *	2003-04-02	2007-11-13	Technion Research & Development Foundation Ltd.	Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
WO2004091510A2 (en)	2003-04-11	2004-10-28	Medimmune, Inc.	Recombinant il-9 antibodies and uses thereof
US20050014932A1 (en)	2003-05-15	2005-01-20	Iogenetics, Llc	Targeted biocides
CA2526720C (en)	2003-05-22	2013-10-22	Fraunhofer Usa, Inc.	Recombinant carrier molecule for expression, delivery and purification of target polypeptides
US20100069614A1 (en)	2008-06-27	2010-03-18	Merus B.V.	Antibody producing non-human mammals
EP1639009B1 (de)	2003-05-30	2013-02-27	Merus B.V.	Fab-bibliothek zur herstellung von einer mischung von antikörpern
US9708410B2 (en)	2003-05-30	2017-07-18	Janssen Biotech, Inc.	Anti-tissue factor antibodies and compositions
WO2005004794A2 (en)	2003-06-09	2005-01-20	Alnylam Pharmaceuticals Inc.	Method of treating neurodegenerative disease
US20050058658A1 (en) *	2003-07-15	2005-03-17	Barros Research Institute	Compositions and methods for immunotherapy of human immunodeficiency virus (HIV)
JP2008500005A (ja) *	2003-07-15	2008-01-10	バロスリサーチインスティテュート	癌及び感染症の免疫療法のための組成物及び方法
US20070274997A1 (en) *	2003-07-25	2007-11-29	Anthony Simmons	Compositions and Methods for Herpes Simplex Prophylaxis and Treatment
CA2445420A1 (en)	2003-07-29	2005-01-29	Invitrogen Corporation	Kinase and phosphatase assays
US7619059B2 (en)	2003-07-29	2009-11-17	Life Technologies Corporation	Bimolecular optical probes
US20050106667A1 (en)	2003-08-01	2005-05-19	Genentech, Inc	Binding polypeptides with restricted diversity sequences
CA2534055A1 (en) *	2003-08-01	2005-02-10	Genentech, Inc.	Antibody cdr polypeptide sequences with restricted diversity
US7758859B2 (en) *	2003-08-01	2010-07-20	Genentech, Inc.	Anti-VEGF antibodies
HN2004000285A (es)	2003-08-04	2006-04-27	Pfizer Prod Inc	ANTICUERPOS DIRIGIDOS A c-MET
EP1668111A4 (de)	2003-08-08	2008-07-02	Genenews Inc	Osteoarthritis-biomarker und verwendungen davon
CA2536238C (en)	2003-08-18	2015-04-07	Medimmune, Inc.	Humanization of antibodies
AR045563A1 (es)	2003-09-10	2005-11-02	Warner Lambert Co	Anticuerpos dirigidos a m-csf
CA2541804A1 (en)	2003-10-07	2005-04-21	Millennium Pharmaceuticals, Inc.	Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
IL158287A0 (en)	2003-10-07	2004-05-12	Yeda Res & Dev	Antibodies to nik, their preparation and use
US20070274988A1 (en) *	2003-10-10	2007-11-29	Five Prime Therapeautics, Inc.	Kiaa0779, Splice Variants Thereof, and Methods of Their Use
US7329725B1 (en) *	2003-10-29	2008-02-12	Nastech Pharmaceutical Company Inc.	Phage displayed Trp cage ligands
JP2005139011A (ja) *	2003-11-04	2005-06-02	Nof Corp	火薬原料及びその製造方法
GB0325836D0 (en) *	2003-11-05	2003-12-10	Celltech R&D Ltd	Biological products
US20050100965A1 (en)	2003-11-12	2005-05-12	Tariq Ghayur	IL-18 binding proteins
SI1983000T1 (sl)	2003-11-21	2015-12-31	Ucb Biopharma Sprl	Postopek za zdravljenje multiple skleroze z zaviranjem aktivnosti il-17
CA2548180C (en) *	2003-12-04	2014-02-04	Vaccinex, Inc.	Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
GB0329825D0 (en) *	2003-12-23	2004-01-28	Celltech R&D Ltd	Biological products
US20050266425A1 (en) *	2003-12-31	2005-12-01	Vaccinex, Inc.	Methods for producing and identifying multispecific antibodies
PT2177537E (pt)	2004-01-09	2011-12-13	Pfizer	Anticorpos contra madcam
NZ548828A (en)	2004-01-20	2009-07-31	Merus B V	Mixtures of binding proteins
EP1714151A4 (de)	2004-01-21	2009-06-10	Fujirebio America Inc	Nachweis von mit mesothelin-/megakaryozyt-potenzierungsfaktor verwandten peptiden in peritonealflüssigkeit zur beurteilung des peritoneums und der peritonealhöhle
ES2567634T3 (es)	2004-02-09	2016-04-25	Human Genome Sciences, Inc.	Proteínas de fusión de albúmina
DE602005018325D1 (de)	2004-02-19	2010-01-28	Genentech Inc	Antikörper mit korrigierten cdr
ES2532609T3 (es) *	2004-02-20	2015-03-30	Ibio, Inc.	Sistemas y métodos para expresión clonales en plantas
JP5557982B2 (ja)	2004-03-01	2014-07-23	イミューンディズィーズインスティテュートインコーポレイテッド	天然ＩｇＭ抗体およびその阻害剤
ATE549625T1 (de)	2004-03-24	2012-03-15	Tripath Imaging Inc	Verfahren und zusammensetzungen zum nachweis einer zervixerkrankung
EP1786463A4 (de) *	2004-03-26	2009-05-20	Human Genome Sciences Inc	Antikörper gegen nogo-rezeptor
TWI556829B (zh)	2004-04-09	2016-11-11	艾伯維生物技術有限責任公司	用於治療ＴＮＦα相關失調症之多重可變劑量療法
US7785903B2 (en) *	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
US7396654B2 (en)	2004-04-15	2008-07-08	University Of Florida Research Foundation, Inc.	Neural proteins as biomarkers for traumatic brain injury
ES2442386T3 (es)	2004-04-23	2014-02-11	Bundesrepublik Deutschland Letztvertreten Durch Das Robert Koch-Institut Vertreten Durch Seinen Pr	Método para el tratamiento de condiciones mediadas por células T por la disminución de las células positivas de ICOS in vivo.
AU2005250369A1 (en) *	2004-05-18	2005-12-15	Genentech, Inc.	M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
CN102453763A (zh)	2004-06-03	2012-05-16	阿什洛米克斯控股有限公司	诊断应激的药物和方法
GB0414054D0 (en)	2004-06-23	2004-07-28	Owen Mumford Ltd	Improvements relating to automatic injection devices
PT1776136E (pt)	2004-06-24	2012-12-05	Biogen Idec Inc	Tratamento de estados que envolvem desmielinização
US7241598B2 (en) *	2004-06-29	2007-07-10	The Chinese University Of Hong Kong	Frame-shifting PCR for germline immunoglobulin genes retrieval and antibody engineering
US6986264B1 (en) *	2004-07-15	2006-01-17	Carrier Corporation	Economized dehumidification system
WO2006008639A1 (en)	2004-07-16	2006-01-26	Pfizer Products Inc.	Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
US7342093B2 (en)	2004-07-23	2008-03-11	University Of Massachusetts	Compounds that inhibit Hsp90 protein-protein interactions with IAP proteins
US7846438B2 (en)	2004-08-03	2010-12-07	Biogen Idec Ma Inc.	Methods of promoting neurite outgrowth with soluble TAJ polypeptides
US20060068421A1 (en) *	2004-08-05	2006-03-30	Biosite, Inc.	Compositions and methods for phage display of polypeptides
DK2322556T3 (en)	2004-09-03	2016-01-25	Genentech Inc	Humanized anti-beta7 antagonists, and uses thereof
EP3073267A1 (de)	2004-09-21	2016-09-28	Medimmune, Inc.	Antikörper gegen und verfahren zur herstellung von impfstoffen für respiratorische synzytialvirus
US7435804B2 (en) *	2004-10-19	2008-10-14	Phage Biotechnology, Inc.	Method for obtaining single chain antibodies to human interferon α2b
WO2006047417A2 (en)	2004-10-21	2006-05-04	University Of Florida Research Foundation, Inc.	Detection of cannabinoid receptor biomarkers and uses thereof
CA2585717A1 (en)	2004-10-27	2006-05-04	Medimmune Inc.	Modulation of antibody specificity by tailoring the affinity to cognate antigens
GB0426146D0 (en)	2004-11-29	2004-12-29	Bioxell Spa	Therapeutic peptides and method
ES2320374T3 (es)	2005-01-05	2009-05-21	F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H.	Dominios de inmunoglobulina sintetica con propiedades de enlace modificadas en regiones de la molecula diferentes de las regiones de determinacion de complementariedad.
GT200600031A (es)	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
EP2520669A3 (de)	2005-02-07	2013-02-27	GeneNews Inc.	Biomarker für milde Arthrose und Verwendungen davon
US20060263357A1 (en)	2005-05-05	2006-11-23	Tedder Thomas F	Anti-CD19 antibody therapy for autoimmune disease
PL1853718T3 (pl)	2005-02-15	2016-01-29	Univ Duke	Przeciwciała anty-CD19 i zastosowania w onkologii
GB0503546D0 (en) *	2005-02-21	2005-03-30	Hellenic Pasteur Inst	Antibody
US20090142338A1 (en) *	2005-03-04	2009-06-04	Curedm, Inc.	Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
EP1858545A2 (de) *	2005-03-04	2007-11-28	Curedm Inc.	Verfahren und pharmazeutische zusammensetzungen zur behandlung von diabetes mellitus typ 1 und anderer erkrankungen
EP1869192B1 (de)	2005-03-18	2016-01-20	MedImmune, LLC	Rahmenmischung von antikörpern
IL296666A (en)	2005-03-23	2022-11-01	Genmab As	Antibodies against 38cd for the treatment of multiple myeloma
GB0506912D0 (en)	2005-04-05	2005-05-11	Celltech R&D Ltd	Biological products
ES2707152T3 (es)	2005-04-15	2019-04-02	Macrogenics Inc	Diacuerpos covalentes y usos de los mismos
US20060269556A1 (en) *	2005-04-18	2006-11-30	Karl Nocka	Mast cell activation using siglec 6 antibodies
CA2605507C (en)	2005-04-19	2016-06-28	Seattle Genetics, Inc.	Humanized anti-cd70 binding agents and uses thereof
CN101272802A (zh)	2005-04-25	2008-09-24	辉瑞大药厂	肌肉生长抑制素的抗体
BRPI0608096A2 (pt)	2005-04-26	2009-11-10	Pfizer	anticorpos p-caderina
US7595380B2 (en)	2005-04-27	2009-09-29	Tripath Imaging, Inc.	Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2006125229A2 (en)	2005-05-16	2006-11-23	Abbott Biotechnology Ltd.	Use of tnf inhibitor for treatment of erosive polyarthritis
EP1899364B2 (de)	2005-05-17	2024-10-30	University of Connecticut	Zusammensetzungen und verfahren zur immunomodulation in einem organismus
US7393919B2 (en)	2005-05-25	2008-07-01	Cure Dm, Inc.	Peptides, derivatives and analogs thereof, and methods of using same
EP2460832A3 (de)	2005-05-27	2012-10-31	Biogen Idec MA Inc.	TWEAK-bindende Antikörper
US7767789B2 (en) *	2005-06-02	2010-08-03	University Hopitals of Cleveland	Truncated proteins as cancer markers
EP1896504B1 (de)	2005-06-17	2012-11-21	Wyeth LLC	VERFAHREN ZUR REINIGUNG FC-REGIONSHALTIGER ANTIKöRPER
KR20080025174A (ko)	2005-06-23	2008-03-19	메디뮨 인코포레이티드	응집 및 단편화 프로파일이 최적화된 항체 제제
CN103145838A (zh) *	2005-06-30	2013-06-12	Abbvie公司	Il-12/p40结合蛋白
AU2006269820B2 (en)	2005-07-07	2012-01-19	Athlomics Pty Ltd	Polynucleotide marker genes and their expression, for diagnosis of endotoxemia
WO2007008604A2 (en) *	2005-07-08	2007-01-18	Bristol-Myers Squibb Company	Single nucleotide polymorphisms associated with dose-dependent edema and methods of use thereof
BRPI0613387A2 (pt)	2005-07-08	2011-01-11	Biogen Idec Inc	anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
CA2617637C (en)	2005-08-02	2017-07-18	Xbiotech Inc.	Diagnosis, treatment, and prevention of vascular disorders using il-1.alpha. autoantibodies
EP1920057A4 (de)	2005-08-03	2009-03-18	Grains Res & Dev Corp	Polysaccharid-synthasen
AU2006341615A1 (en) *	2005-08-03	2007-10-18	Fraunhofer Usa, Inc.	Compositions and methods for production of immunoglobulins
NZ612578A (en)	2005-08-19	2014-11-28	Abbvie Inc	Dual variable domain immunoglobin and uses thereof
US20090215992A1 (en) *	2005-08-19	2009-08-27	Chengbin Wu	Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) *	2005-08-19	2009-11-03	Abbott Laboratories	Dual variable domain immunoglobulin and uses thereof
EP2500359A3 (de)	2005-08-19	2012-10-17	Abbott Laboratories	Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
US20070041905A1 (en)	2005-08-19	2007-02-22	Hoffman Rebecca S	Method of treating depression using a TNF-alpha antibody
US20070202512A1 (en) *	2005-08-19	2007-08-30	Bristol-Myers Squibb Company	Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
EP1933871B1 (de)	2005-09-07	2013-04-24	Amgen Fremont Inc.	Humane monoklonale antikörper gegen activin-rezeptor-artige kinase-1
ES2382879T3 (es) *	2005-09-14	2012-06-14	Ucb Pharma, S.A.	Conjugado de anticuerpo - polímero de peine.
JP2009510002A (ja)	2005-09-30	2009-03-12	アボットゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフト	反発誘導分子（ｒｇｍ）タンパク質ファミリーのタンパク質の結合ドメイン、及びその機能的断片、及びそれらの使用
GB0520169D0 (en) *	2005-10-04	2005-11-09	Celltech R&D Ltd	Biological products
JP5237817B2 (ja)	2005-10-21	2013-07-17	ジーンニュースインコーポレーティッド	バイオマーカー産物レベルを疾患に相関させるための方法および装置
EP2862867A3 (de)	2005-10-25	2015-08-05	The Johns Hopkins University	Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen
CA2626325A1 (en)	2005-10-28	2007-05-10	Praecis Pharmaceuticals Incorporated	Methods for identifying compounds of interest using encoded libraries
TWI424161B (zh)	2005-11-01	2014-01-21	Abbvie Biotechnology Ltd	利用生物標記診斷關節黏連脊椎炎之方法及組合物
AU2006311828B2 (en)	2005-11-04	2013-07-11	Biogen Ma Inc.	Methods for promoting neurite outgrowth and survival of dopaminergic neurons
CN101500592A (zh)	2005-11-07	2009-08-05	斯克利普斯研究院	控制组织因子信号转导特异性的组合物和方法
ES2577292T3 (es)	2005-11-07	2016-07-14	Genentech, Inc.	Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
UA96139C2 (uk)	2005-11-08	2011-10-10	Дженентек, Інк.	Антитіло до нейропіліну-1 (nrp1)
US7807790B2 (en)	2005-11-14	2010-10-05	Metamol Theranostics, Llc	Peptide sequence that promotes tumor invasion
PL1963369T3 (pl)	2005-11-28	2013-10-31	Zymogenetics Inc	Antagoniści IL-21
MX2008006945A (es)	2005-11-30	2008-10-02	Massachusetts Inst Technology	Biosensor de deteccion de patogeno.
KR20140087058A (ko)	2005-11-30	2014-07-08	애브비 인코포레이티드	아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
AU2006319358B2 (en)	2005-11-30	2012-01-19	AbbVie Deutschland GmbH & Co. KG	Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
AU2006338198B2 (en) *	2005-12-02	2012-04-26	Genentech, Inc.	Binding polypeptides and uses thereof
EP1973951A2 (de) *	2005-12-02	2008-10-01	Genentech, Inc.	Bindende polypeptide mit eingeschränkten diversitätssequenzen
EP2543384A3 (de)	2005-12-02	2013-04-10	Biogen Idec MA Inc.	Behandlung von Zuständen mithilfe von Demyelinisation
KR101413451B1 (ko)	2005-12-09	2014-07-10	유씨비 파마, 에스.에이.	사람 ｉｌ6에 특이성을 지니는 항체 분자
US10183986B2 (en)	2005-12-15	2019-01-22	Industrial Technology Research Institute	Trimeric collagen scaffold antibodies
US8014957B2 (en)	2005-12-15	2011-09-06	Fred Hutchinson Cancer Research Center	Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US20070264687A1 (en)	2005-12-15	2007-11-15	Min-Yuan Chou	Recombinant triplex scaffold-based polypeptides
US7632498B2 (en)	2005-12-19	2009-12-15	Tripath Imaging, Inc.	MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
US8669345B2 (en)	2006-01-27	2014-03-11	Biogen Idec Ma Inc.	Nogo receptor antagonists
EP1987360B1 (de)	2006-01-27	2012-03-07	Tripath Imaging, Inc.	Verfahren zur identifizierung von patienten mit erhöhter wahrscheinlichkeit des auftretens eines ovarialkarzinoms und zusammensetzungen dafür
US20080038761A1 (en) *	2006-01-30	2008-02-14	Invitrogen Corporation	Compositions and methods for detecting and quantifying toxic substances in disease states
US20070175313A1 (en) *	2006-01-31	2007-08-02	Kevin Vandervliet	MP3 player holder assembly
US8277816B2 (en) *	2006-02-13	2012-10-02	Fraunhofer Usa, Inc.	Bacillus anthracis antigens, vaccine compositions, and related methods
JP2009526526A (ja) *	2006-02-13	2009-07-23	フラウンホーファーユーエスエー，インコーポレイテッド	インフルエンザ抗原、ワクチン組成物、および関連する方法
JP2009526780A (ja) *	2006-02-13	2009-07-23	フラウンホーファーユーエスエー，インコーポレイテッド	Ｈｐｖ抗原、ワクチン組成物、および関連する方法
TW200744634A (en)	2006-02-21	2007-12-16	Wyeth Corp	Methods of using antibodies against human IL-22
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
EP1999148B8 (de)	2006-03-06	2014-03-05	Medlmmune, LLC	Humanisierte anti-cd22-antikörper und ihre verwendung für die behandlung von krebs, transplantationen und autoimmunerkrankungen
EP2010569A4 (de)	2006-03-20	2009-09-09	Xoma Technology Ltd	Für gastrin spezifische humane antikörper, materialien und methoden
TWI392684B (zh)	2006-04-05	2013-04-11	亞培生物科技公司	抗體之純化
EP2703010A3 (de)	2006-04-10	2014-08-06	AbbVie Biotechnology Ltd	Anwendungen und Zusammensetzungen zur Behandlung von rheumatoider Arthritis
CA2564435A1 (en)	2006-04-10	2007-10-10	Abbott Biotechnology Ltd.	Methods for monitoring and treating intestinal disorders
EP2666472A3 (de)	2006-04-10	2014-04-02	Abbott Biotechnology Ltd	Anwendungen und Zusammensetzungen zur Behandlung von Psoriasis-Arthritis
US10522240B2 (en)	2006-05-03	2019-12-31	Population Bio, Inc.	Evaluating genetic disorders
US7702468B2 (en)	2006-05-03	2010-04-20	Population Diagnostics, Inc.	Evaluating genetic disorders
EP2016101A2 (de) *	2006-05-09	2009-01-21	Genentech, Inc.	Bindung von polypeptiden mit optimierten gerüsten
US20090318308A1 (en) *	2006-05-30	2009-12-24	Millegen	Highly diversified antibody libraries
GB0611116D0 (en)	2006-06-06	2006-07-19	Oxford Genome Sciences Uk Ltd	Proteins
AU2007260687B2 (en)	2006-06-14	2013-12-12	Provention Bio, Inc.	Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
JP5764290B2 (ja)	2006-06-26	2015-08-19	マクロジェニクス，インコーポレーテッド	ＦｃγＲＩＩＢ特異的抗体およびその使用法
KR101396797B1 (ko)	2006-06-30	2014-05-26	애브비 바이오테크놀로지 리미티드	자동 주사 장치
US7572618B2 (en)	2006-06-30	2009-08-11	Bristol-Myers Squibb Company	Polynucleotides encoding novel PCSK9 variants
AT503889B1 (de)	2006-07-05	2011-12-15	Star Biotechnologische Forschungs Und Entwicklungsges M B H F	Multivalente immunglobuline
AU2007307260B2 (en)	2006-07-05	2013-02-28	Catalyst Biosciences, Inc.	Protease screening methods and proteases identified thereby
EP3796002B1 (de)	2006-07-14	2023-11-22	The Regents of The University of California	Krebsbiomarker und verfahren zur verwendung davon
CA2658276A1 (en)	2006-07-18	2008-01-24	Sanofi-Aventis	Antagonist antibody for the treatment of cancer
CN101522717A (zh)	2006-08-04	2009-09-02	阿斯利康(瑞典)有限公司	针对ErbB2的人抗体
KR101314362B1 (ko)	2006-08-28	2013-10-10	라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지	길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체
ES2902063T3 (es) *	2006-09-08	2022-03-24	Abbvie Bahamas Ltd	Proteínas de unión a interleucina-13
HRP20191115T1 (hr)	2006-09-26	2019-09-20	Genmab A/S	Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
TWI414531B (zh)	2006-10-12	2013-11-11	Genentech Inc	淋巴毒素α之抗體
EP2076287A2 (de)	2006-10-12	2009-07-08	Wyeth	Verfahren und zusammensetzungen mit verringerter opaleszenz
WO2008048545A2 (en)	2006-10-16	2008-04-24	Medimmune, Llc.	Molecules with reduced half-lives, compositions and uses thereof
GB0620729D0 (en)	2006-10-18	2006-11-29	Ucb Sa	Biological products
EP1914242A1 (de)	2006-10-19	2008-04-23	Sanofi-Aventis	Neue Antikörper gegen CD38 zur Behandlung von Krebs
EP2395077A1 (de)	2006-11-03	2011-12-14	Wyeth LLC	Glycolysehemmstoffe in Zellkulturen
EP1921142A1 (de) *	2006-11-07	2008-05-14	Cytos Biotechnology AG	Auswahl von menschlichen monoklonalen Antikörpern unter Verwendung von eukaryontischem Zell-Display
KR20090088896A (ko)	2006-11-09	2009-08-20	아이알엠 엘엘씨	효현제 ｔｒｋｂ 항체 및 그의 용도
CA2669095A1 (en)	2006-11-15	2008-05-29	Functional Genetics, Inc.	Anti-tsg101 antibodies and their uses for treatment of viral infections
US7488807B2 (en)	2006-11-22	2009-02-10	3M Innovative Properties Company	Antibody with protein A selectivity
US8785400B2 (en) *	2006-11-22	2014-07-22	Curedm Group Holdings, Llc	Methods and compositions relating to islet cell neogenesis
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8455622B2 (en)	2006-12-01	2013-06-04	Seattle Genetics, Inc.	Variant target binding agents and uses thereof
EP2687232A1 (de)	2006-12-06	2014-01-22	MedImmune, LLC	Verfahren zur Behandlung von systemischem Lupus erythematodes
EP2094306A2 (de)	2006-12-20	2009-09-02	XOMA Technology Ltd.	Behandlung von il-1-beta-bedingten erkrankungen
CN103536915A (zh)	2006-12-27	2014-01-29	埃默里大学	用于治疗传染病和肿瘤的组合物和方法
NO2740744T3 (de)	2007-01-09	2018-08-25
US8128926B2 (en)	2007-01-09	2012-03-06	Biogen Idec Ma Inc.	Sp35 antibodies and uses thereof
AU2008205512B2 (en)	2007-01-16	2014-06-12	Abbvie Inc.	Methods for treating psoriasis
SG193026A1 (en)	2007-02-07	2013-09-30	Decode Genetics Ehf	Genetic variants contributing to risk of prostate cancer
WO2008100805A2 (en)	2007-02-09	2008-08-21	Genentech, Inc.	Anti-robo4 antibodies and uses therefor
US8685666B2 (en)	2007-02-16	2014-04-01	The Board Of Trustees Of Southern Illinois University	ARL-1 specific antibodies and uses thereof
US8114606B2 (en)	2007-02-16	2012-02-14	The Board Of Trustees Of Southern Illinois University	ARL-1 specific antibodies
EA022610B1 (ru)	2007-02-21	2016-02-29	Декоуд Дженетикс Ехф	Способ определения предрасположенности к сердечно-сосудистым заболеваниям с применением полиморфных маркеров
EP2121745A2 (de)	2007-02-26	2009-11-25	Oxford Genome Sciences (UK) Limited	Proteine
WO2008104803A2 (en)	2007-02-26	2008-09-04	Oxford Genome Sciences (Uk) Limited	Proteins
US8895004B2 (en)	2007-02-27	2014-11-25	AbbVie Deutschland GmbH & Co. KG	Method for the treatment of amyloidoses
BRPI0809042B1 (pt)	2007-03-22	2021-08-31	Biogen Ma Inc.	Proteína de ligação a cd154 isolada, seu uso, e composição
CA2681415C (en)	2007-03-22	2020-11-03	Heptares Therapeutics Limited	Mutant g-protein coupled receptors and methods for selecting them
US20100209434A1 (en)	2007-03-30	2010-08-19	Medimmune, Llc	Antibody formulation
TW200904470A (en)	2007-04-02	2009-02-01	Pfizer	Anti-IgE antibodies
EP2132339B1 (de) *	2007-04-04	2011-03-09	Chimera Biotec GmbH	Verfahren zum nachweis eines analyten in einer biologischen matrix
US7807168B2 (en) *	2007-04-10	2010-10-05	Vaccinex, Inc.	Selection of human TNFα specific antibodies
CN101743309B (zh)	2007-04-13	2014-01-29	催化剂生物科学公司	修饰的因子ⅶ多肽及其应用
TW200902708A (en)	2007-04-23	2009-01-16	Wyeth Corp	Methods of protein production using anti-senescence compounds
US8778348B2 (en) *	2007-04-28	2014-07-15	Ibio Inc.	Trypanosoma antigens, vaccine compositions, and related methods
AU2008246442B2 (en)	2007-05-04	2014-07-03	Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa	Engineered rabbit antibody variable domains and uses thereof
KR20100017514A (ko)	2007-05-07	2010-02-16	메디뮨 엘엘씨	항 ｉｃｏｓ 항체, 및 종양, 이식 및 자가면역성 질환 치료에서의 이의 용도
WO2008143666A2 (en)	2007-05-17	2008-11-27	Genentech, Inc.	Crystal structures of neuropilin fragments and neuropilin-antibody complexes
SG10202000728UA (en)	2007-05-14	2020-03-30	Astrazeneca Ab	Methods of reducing eosinophil levels
EA018444B1 (ru)	2007-05-25	2013-08-30	Декоуд Дженетикс Ехф.	ГЕНЕТИЧЕСКИЕ ВАРИАНТЫ В Chr 5p12 И 10q26 В КАЧЕСТВЕ МАРКЕРОВ ДЛЯ ПРИМЕНЕНИЯ ПРИ ОЦЕНКЕ РИСКА, ДИАГНОСТИРОВАНИИ, ПРОГНОЗИРОВАНИИ И ЛЕЧЕНИИ РАКА ГРУДИ
US20090175847A1 (en) *	2007-05-30	2009-07-09	Abbott Laboratories	Humanized antibodies to ab (20-42) globulomer and uses thereof
US20090232801A1 (en) *	2007-05-30	2009-09-17	Abbot Laboratories	Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
US8999337B2 (en)	2007-06-11	2015-04-07	Abbvie Biotechnology Ltd.	Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
EP2170956B1 (de)	2007-06-15	2014-10-22	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Behandlung von tumoren unter anwendung eines spezifischen anti-l1-antikörpers
PL2158221T3 (pl)	2007-06-21	2019-02-28	Macrogenics, Inc.	Kowalencyjne diaciała i ich zastosowania
JP5602625B2 (ja) *	2007-06-26	2014-10-08	エフ−スタービオテヒノロギッシェフォルシュングス− ウントエントヴィッケルングスゲゼルシャフトミットベシュレンクテルハフツング	結合物質のディスプレイ
WO2009009759A2 (en) *	2007-07-11	2009-01-15	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
CN111499748A (zh)	2007-07-16	2020-08-07	健泰科生物技术公司	抗cd79b抗体和免疫偶联物及使用方法
NZ583318A (en)	2007-07-16	2012-07-27	Genentech Inc	Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DK3031919T3 (en)	2007-07-31	2019-01-07	Basf Enzymes Llc	Tailored multi-site combination device
WO2009020477A1 (en) *	2007-08-06	2009-02-12	Yale University	Modified miniature proteins
EP2190472A2 (de) *	2007-08-20	2010-06-02	Fraunhofer USA, Inc.	Prophylaktische und therapeutische influenza-vakzine, antigene, zusammensetzungen und verfahren
DK2193142T3 (da) *	2007-08-30	2015-04-20	Curedm Group Holdings Llc	Præparater og fremgangsmåder til anvendelse af pro-øcellepeptider og analoger dertil
GB0717337D0 (en)	2007-09-06	2007-10-17	Ucb Pharma Sa	Method of treatment
US8877688B2 (en)	2007-09-14	2014-11-04	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
CA3187687A1 (en)	2007-09-14	2009-03-19	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
US12529164B2 (en)	2007-09-14	2026-01-20	Adimab, Llc	Rationally designed, synthetic antibody libraries and uses therefor
EP2535350B1 (de)	2007-09-26	2018-01-24	UCB Biopharma SPRL	Antikörperfusionen mit Doppelspezifität
US9150849B2 (en) *	2007-11-02	2015-10-06	The Scripps Research Institute	Directed evolution using proteins comprising unnatural amino acids
NZ585064A (en)	2007-11-05	2012-08-31	Medimmune Llc	Methods of treating scleroderma
JP5809415B2 (ja)	2007-11-09	2015-11-10	ペレグリンファーマシューティカルズ，インコーポレーテッド	抗ｖｅｇｆ抗体の組成物および方法
EP3115469B1 (de)	2007-11-19	2020-04-29	Celera Corporation	Lungenkrebsmarker und verwendungen davon
JP5490714B2 (ja)	2007-11-28	2014-05-14	メディミューン，エルエルシー	タンパク質製剤
US8697360B2 (en)	2007-11-30	2014-04-15	Decode Genetics Ehf.	Genetic variants on CHR 11Q and 6Q as markers for prostate and colorectal cancer predisposition
AR069501A1 (es) *	2007-11-30	2010-01-27	Genentech Inc	Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
GB0724051D0 (en)	2007-12-08	2008-01-16	Medical Res Council	Mutant proteins and methods for producing them
AU2008343589A1 (en)	2007-12-19	2009-07-09	Centocor Ortho Biotech Inc.	Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
GB0724860D0 (en)	2007-12-20	2008-01-30	Heptares Therapeutics Ltd	Screening
EP2391650B1 (de)	2007-12-20	2014-10-15	Xoma (Us) Llc	Verfahren zur behandlung von gicht
WO2009082485A1 (en)	2007-12-26	2009-07-02	Vaccinex, Inc.	Anti-c35 antibody combination therapies and methods
EA028356B1 (ru)	2007-12-28	2017-11-30	Протена Байосайенсиз Лимитед	Лечение и профилактика амилоидоза
GB0800277D0 (en)	2008-01-08	2008-02-13	Imagination Tech Ltd	Video motion compensation
KR101597842B1 (ko)	2008-01-11	2016-02-25	가부시키가이샤 진 테크노 사이언스	인간화된 항-알파9 인테그린 항체 및 그의 용도
AU2009205995B2 (en)	2008-01-18	2014-04-03	Medimmune, Llc	Cysteine engineered antibodies for site-specific conjugation
ES2587392T3 (es)	2008-01-31	2016-10-24	Genentech, Inc.	Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
MX2010008578A (es)	2008-02-08	2010-11-10	Medimmune Llc	Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
GB0802474D0 (en)	2008-02-11	2008-03-19	Heptares Therapeutics Ltd	Mutant proteins and methods for selecting them
NZ587903A (en)	2008-02-14	2013-05-31	Decode Genetics Ehf	Susceptibility for lung cancer using the polymorphic marker rs1051730
CN101980723A (zh)	2008-02-28	2011-02-23	3M创新有限公司	艰难梭菌芽孢的抗体及其用途
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
WO2009114815A1 (en)	2008-03-13	2009-09-17	Dyax Corp	Libraries of genetic packages comprising novel hc cdr3 designs
US8178092B2 (en)	2008-03-18	2012-05-15	Abbott Laboratories	Methods of treating psoriasis by administration of antibodies to the p40 subunit of IL-12 and/or IL-23
EP2260102A1 (de)	2008-03-25	2010-12-15	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
EP2274450A2 (de)	2008-04-01	2011-01-19	Decode Genetics EHF	Suszeptibilitätsvarianten bei peripherer arterienkrankheit und bauchschlagader-aneurysma
CN107236044B (zh)	2008-04-02	2021-07-02	宏观基因有限公司	HER2/neu-特异性抗体和其使用方法
CN102046655B (zh)	2008-04-02	2016-09-14	宏观基因有限公司	Bcr-复合体-特异性抗体和其使用方法
KR101674097B1 (ko)	2008-04-11	2016-11-08	시애틀 지네틱스, 인크.	췌장, 난소 및 다른 암의 검출 및 치료
GB0807413D0 (en)	2008-04-23	2008-05-28	Ucb Pharma Sa	Biological products
CA2721716C (en)	2008-04-24	2019-09-24	Gene Techno Science Co., Ltd.	Humanized antibodies specific for amino acid sequence rgd of an extracellular matrix protein and the uses thereof
CA2968164C (en) *	2008-04-24	2019-08-20	Dyax Corp.	Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
BRPI0910622A2 (pt)	2008-04-25	2020-03-10	Dyax Corp.	ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
US20090269786A1 (en) *	2008-04-25	2009-10-29	The Board Of Trustees Of The University Of Illinois	RHO1-Gamma Amino Butyric Acid C Receptor-Specific Antibodies
AU2009241589B2 (en)	2008-04-29	2013-10-10	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
PL2282773T3 (pl)	2008-05-02	2014-08-29	Seattle Genetics Inc	Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
EP2113255A1 (de)	2008-05-02	2009-11-04	f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H.	Zytotoxisches Immunglobulin
CN102089430B (zh)	2008-05-09	2015-02-04	Abbvie公司	针对渐进性糖化终极产物受体(rage)的抗体及其用途
WO2009140684A2 (en) *	2008-05-16	2009-11-19	Genentech, Inc.	Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
US20090291073A1 (en) *	2008-05-20	2009-11-26	Ward Keith W	Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
EP2304439A4 (de)	2008-05-29	2012-07-04	Nuclea Biotechnologies Llc	Anti-phospho-akt-antikörper
EP3002299A1 (de)	2008-06-03	2016-04-06	AbbVie Inc.	Dual-variable- domain-immunglobuline und ihre verwendungen
US9109026B2 (en)	2008-06-03	2015-08-18	Abbvie, Inc.	Dual variable domain immunoglobulins and uses thereof
EP2282770B1 (de)	2008-06-04	2018-03-07	MacroGenics, Inc.	Antikörper mit veränderter bindung an fcrn und verwendungsverfahren dafür
CN102316894A (zh)	2008-06-20	2012-01-11	惠氏有限责任公司	来自β-溶血性链球菌菌株的ORF1358的组合物和使用方法
NZ590833A (en)	2008-07-07	2013-01-25	Decode Genetics Ehf	Genetic variants for breast cancer risk assessment
JP2011527579A (ja)	2008-07-08	2011-11-04	アボット・ラボラトリーズ	プロスタグランジンｅ２結合タンパク質およびこの使用
TW201012475A (en)	2008-07-08	2010-04-01	Abbott Lab	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
CA2729961C (en)	2008-07-09	2018-05-01	Biogen Idec Ma Inc.	Li113, li62 variant co2, anti-lingo antibodies
MY153074A (en)	2008-08-14	2014-12-31	Teva Pharmaceuticals Australia Pty Ltd	Anti-il-12/11-23 antibodies
CA3073384A1 (en)	2008-09-05	2010-03-11	President And Fellows Of Harvard College	Continuous directed evolution of proteins and nucleic acids
WO2010033237A2 (en) *	2008-09-22	2010-03-25	Calmune Corporation	Methods for creating diversity in libraries and libraries, display vectors and methods, and displayed molecules
US20100093563A1 (en) *	2008-09-22	2010-04-15	Robert Anthony Williamson	Methods and vectors for display of molecules and displayed molecules and collections
CA2739357A1 (en)	2008-09-23	2010-04-08	Wyeth Llc	Methods for predicting production of activating signals by cross-linked binding proteins
EP2352841A2 (de)	2008-09-23	2011-08-10	President and Fellows of Harvard College	Sirt4 und verwendungen davon
CN102264762B (zh)	2008-09-26	2018-03-27	达纳-法伯癌症研究公司	人抗pd‑1、pd‑l1和pd‑l2的抗体及其应用
US8313942B2 (en)	2008-09-26	2012-11-20	Wyeth Llc	Compatible display vector systems
WO2010037046A1 (en)	2008-09-28	2010-04-01	Fraunhofer Usa, Inc.	Humanized neuraminidase antibody and methods of use thereof
EP3025727A1 (de)	2008-10-02	2016-06-01	The J. David Gladstone Institutes	Verfahren zur behandlung von lebererkrankungen
SMT202000101T1 (it)	2008-10-10	2020-03-13	Childrens Medical Center	Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
EP2349329A4 (de)	2008-10-14	2012-10-31	Dyax Corp	Verwendung von igf-ii/igf-iie-bindung zur behandlung und prävention von systemischer sklerose im zusammenhang mit lungenfibrose
RU2520838C2 (ru)	2008-10-20	2014-06-27	Эббви Инк	Выделение и очистка антител с использованием аффинной хроматографии на основе белка а
EP3351628B1 (de)	2008-10-24	2023-07-26	The Government of The United States of America as represented by The Secretary, Department of Health and Human Services	Menschliche ebola-virus-spezies und zusammensetzungen und verfahren dafür
AU2009314311B2 (en)	2008-10-29	2013-01-10	Ablynx N.V.	Methods for purification of single domain antigen binding molecules
ES2732504T3 (es)	2008-10-29	2019-11-22	Circular Commitment Company	Procedimientos y agentes para el diagnóstico y tratamiento del carcinoma hepatocelular
AR073997A1 (es)	2008-10-29	2010-12-15	Wyeth Corp	Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
US20110293605A1 (en)	2008-11-12	2011-12-01	Hasige Sathish	Antibody formulation
DK2189539T4 (en) *	2008-11-21	2018-09-17	Chimera Biotec Gmbh	Conjugate complexes for analyte detection
AU2009319772A1 (en)	2008-11-26	2010-06-03	Centocor Research & Development, Inc.	Compositions and methods for regulating collagen and smooth muscle actin expression by SERPINE2
MX2011005691A (es)	2008-11-28	2011-07-20	Univ Emory	Metodos para el tratamiento de infecciones y tumores.
NZ593314A (en) *	2008-12-04	2013-03-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
BRPI0917592B1 (pt)	2008-12-09	2021-08-17	Genentech, Inc	Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
AU2009335798B2 (en)	2008-12-19	2014-11-27	Macrogenics, Inc.	Covalent diabodies and uses thereof
CN102341411A (zh)	2008-12-31	2012-02-01	比奥根艾迪克Ma公司	抗-淋巴细胞毒素抗体
WO2010080985A1 (en)	2009-01-08	2010-07-15	Dana-Farber Cancer Institute, Inc.	Compositions and methods for induced brown fat differentiation
GB0900425D0 (en)	2009-01-12	2009-02-11	Ucb Pharma Sa	Biological products
WO2010082134A1 (en)	2009-01-14	2010-07-22	Iq Therapeutics Bv	Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
EP2389195B1 (de)	2009-01-20	2015-05-20	Homayoun H. Zadeh	Antikörpervermittelte knochenregeneration
WO2010084408A2 (en)	2009-01-21	2010-07-29	Oxford Biotherapeutics Ltd.	Pta089 protein
US20110165063A1 (en) *	2009-01-29	2011-07-07	Abbott Laboratories	Il-1 binding proteins
RU2011135768A (ru)	2009-01-29	2013-03-10	Эбботт Лэборетриз	Белки, связывающие il-1
WO2010087702A1 (en)	2009-01-30	2010-08-05	Stichting Katholieke Universiteit	TET2 gene as a marker for diagnosing a myelodysuplastic syndrome (MDS) or an acute myeloid leukemia (AML) and determining the prognosis in a subject
WO2010087927A2 (en)	2009-02-02	2010-08-05	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en)	2009-02-12	2010-08-19	Human Genome Sciences, Inc.	Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
SG2014014708A (en)	2009-02-17	2014-05-29	Ucb Pharma Sa	Antibody molecules having specificity for human ox40
US8030026B2 (en)	2009-02-24	2011-10-04	Abbott Laboratories	Antibodies to troponin I and methods of use thereof
RU2011140335A (ru)	2009-03-05	2013-04-10	Эбботт Лэборетриз	Связывающие il-17 белки
EP2403880A1 (de)	2009-03-05	2012-01-11	Tripath Imaging, Inc.	Monoklonale antikörper gegen matrixmetalloproteinase-7 (mmp-7) und verfahren zu ihrer verwendung beim nachweis von eierstockkrebs
JP2012524521A (ja)	2009-03-06	2012-10-18	トライパスイメージングインコーポレイテッド	グリコデリンモノクローナル抗体および卵巣癌の検出におけるその使用のための方法
EP2405920A1 (de)	2009-03-06	2012-01-18	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Neue therapie gegen angstzustände
AU2010221993C1 (en)	2009-03-10	2015-07-09	Gene Techno Science Co., Ltd.	Generation, expression and characterization of the humanized K33N monoclonal antibody
GB0904214D0 (en)	2009-03-11	2009-04-22	Ucb Pharma Sa	Biological products
SG174992A1 (en)	2009-04-01	2011-11-28	Genentech Inc	Anti-fcrh5 antibodies and immunoconjugates and methods of use
NZ595918A (en)	2009-04-03	2013-07-26	Decode Genetics Ehf	Genetic markers for risk management of atrial fibrillation and stroke
EP2241323A1 (de)	2009-04-14	2010-10-20	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Tenascin-W und Hirnkrebs
EP3009454A3 (de)	2009-04-20	2016-10-19	Oxford Bio Therapeutics Limited	Antikörper spezifisch gegen cadherin-17
CA2760237C (en)	2009-04-29	2017-11-14	Abbott Biotechnology Ltd.	Automatic injection device and plunger for same
EP2799453B1 (de)	2009-04-29	2019-04-03	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.	Monoklonale ERG2-Antikörper und deren therapeutische Verwendung
WO2010129033A2 (en) *	2009-04-29	2010-11-11	Calmune Corporation	Modified antibodies for passive immunotherapy
MX2011012299A (es)	2009-05-20	2012-03-29	Novimmune Sa	Librerias de polipeptidos sinteticos y metodos para generar variantes de polipeptido naturalmente diversificadas.
EP2261242A1 (de)	2009-06-10	2010-12-15	Universite Catholique De Louvain	Aspartat-N-Acetyltransferaseenzym, Diagnoseverfahren und therapeutisches Verfahren
US20120213705A1 (en)	2009-06-22	2012-08-23	Medimmune, Llc	ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
GB0910725D0 (en)	2009-06-22	2009-08-05	Heptares Therapeutics Ltd	Mutant proteins and methods for producing them
EP2272979A1 (de)	2009-06-30	2011-01-12	Centre National de la Recherche Scientifique (CNRS)	Verfahren zum Testen einer Person, die eine Prädisposition für Krebs aufzuweisen scheint
SG177583A1 (en)	2009-07-09	2012-02-28	Hoffmann La Roche	In vivo tumor vasculature imaging
NZ598009A (en)	2009-07-10	2013-11-29	Decode Genetics Ehf	Genetic markers associated with risk of diabetes mellitus
US9259476B2 (en)	2009-07-31	2016-02-16	Wayne State University	Monophosphorylated lipid A derivatives
CN102596220A (zh)	2009-07-31	2012-07-18	韦恩州立大学	单磷酸化的脂质a衍生物
ES2553440T3 (es)	2009-08-13	2015-12-09	Crucell Holland B.V.	Anticuerpos contra el virus sincitial respiratorio humano (VSR) y método de uso
EP2292266A1 (de)	2009-08-27	2011-03-09	Novartis Forschungsstiftung, Zweigniederlassung	Behandlung von Krebs durch Modulation von Copine III
AU2010286518C1 (en)	2009-08-29	2015-08-27	Abbvie Inc.	Therapeutic DLL4 binding proteins
US20110059111A1 (en)	2009-09-01	2011-03-10	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
AU2010289527C1 (en)	2009-09-01	2014-10-30	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
WO2011030107A1 (en)	2009-09-10	2011-03-17	Ucb Pharma S.A.	Multivalent antibodies
CA2773564A1 (en) *	2009-09-14	2011-03-17	Dyax Corp.	Libraries of genetic packages comprising novel hc cdr3 designs
EP2478101A1 (de)	2009-09-16	2012-07-25	Stichting Het Nederlands Kanker Instituut	Fra-1-zielgene als wirkstofftargets zur behandlung von krebs
WO2011035205A2 (en)	2009-09-18	2011-03-24	Calmune Corporation	Antibodies against candida, collections thereof and methods of use
EP2305717A1 (de)	2009-09-21	2011-04-06	Koninklijke Nederlandse Akademie van Wetenschappen	Hemmung von TNIK zur Behandlung von Darmkrebs
WO2011036118A1 (en)	2009-09-22	2011-03-31	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Treating cancer by modulating mex-3
US8926976B2 (en)	2009-09-25	2015-01-06	Xoma Technology Ltd.	Modulators
AU2010298036B2 (en)	2009-09-25	2015-05-21	Xoma Technology Ltd.	Screening methods
AU2010298025B2 (en)	2009-09-25	2016-04-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neutralizing antibodies to HIV-1 and their use
GB201005063D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
WO2011036555A1 (en)	2009-09-25	2011-03-31	University Of Oslo	Multivalent phage display systems and methods
WO2011041391A1 (en)	2009-09-29	2011-04-07	Fraunhofer Usa, Inc.	Influenza hemagglutinin antibodies, compositions, and related methods
JP2013506687A (ja)	2009-09-30	2013-02-28	プレジデントアンドフェロウズオブハーバードカレッジ	オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法
UY32914A (es)	2009-10-02	2011-04-29	Sanofi Aventis	Anticuerpos que se usan específicamente al receptor epha2
US20120231004A1 (en)	2009-10-13	2012-09-13	Oxford Biotherapeutic Ltd.	Antibodies
WO2011045352A2 (en)	2009-10-15	2011-04-21	Novartis Forschungsstiftung	Spleen tyrosine kinase and brain cancers
BR112012008833A2 (pt)	2009-10-15	2015-09-08	Abbott Lab	imunoglobulinas de dominio variavel duplo e usos das mesmas
KR20170136649A (ko)	2009-10-20	2017-12-11	애브비 인코포레이티드	단백질 ａ 친화성 크로마토그래피를 사용한 항―ｉｌ―１３ 항체의 분리 및 정제
GB0922434D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	antibodies and fragments thereof
US20110098862A1 (en)	2009-10-27	2011-04-28	ExxonMobil Research Engineering Company Law Department	Multi-stage processes and control thereof
WO2011051350A1 (en)	2009-10-27	2011-05-05	Ucb Pharma S.A.	Function modifying nav 1.7 antibodies
GB0922435D0 (en)	2009-12-22	2010-02-03	Ucb Pharma Sa	Method
US9234037B2 (en)	2009-10-27	2016-01-12	Ucb Biopharma Sprl	Method to generate antibodies to ion channels
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120213801A1 (en)	2009-10-30	2012-08-23	Ekaterina Gresko	Phosphorylated Twist1 and cancer
US8420083B2 (en)	2009-10-31	2013-04-16	Abbvie Inc.	Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
EP2496605A1 (de)	2009-11-02	2012-09-12	Oxford Biotherapeutics Ltd.	Ror1 als therapeutisches und diagnostisches ziel
US9244063B2 (en)	2009-11-11	2016-01-26	Gentian As	Immunoassay for assessing related analytes of different origin
EP3168232B1 (de)	2009-11-13	2021-09-29	Dana-Farber Cancer Institute, Inc.	Zusammensetzungen, kits und verfahren zur diagnose, prognose, überwachung, behandlung und modulierung von auf transplantationen folgenden lymphoproliferativen erkrankungen und hypoxievermittelten angiogeneseerkrankungen mithilfe von galectin-1
JP5955773B2 (ja)	2009-11-17	2016-07-20	ヤンセンバイオテツク，インコーポレーテツド	改善された細菌膜タンパク質分泌
GB0920127D0 (en)	2009-11-17	2009-12-30	Ucb Pharma Sa	Antibodies
GB0920324D0 (en)	2009-11-19	2010-01-06	Ucb Pharma Sa	Antibodies
JP5951498B2 (ja)	2009-12-08	2016-07-13	アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー	網膜神経線維層変性の治療に使用するためのｒｇｍａタンパク質に対するモノクローナル抗体
WO2011085103A2 (en)	2010-01-06	2011-07-14	Dyax Corp.	Plasma kallikrein binding proteins
GB201000467D0 (en)	2010-01-12	2010-02-24	Ucb Pharma Sa	Antibodies
US9745589B2 (en)	2010-01-14	2017-08-29	Cornell University	Methods for modulating skeletal remodeling and patterning by modulating SHN2 activity, SHN3 activity, or SHN2 and SHN3 activity in combination
US10429384B2 (en)	2010-01-22	2019-10-01	Dana-Farber Cancer Institute, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
WO2011097301A2 (en)	2010-02-02	2011-08-11	Abbott Biotechnology Ltd.	METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
EP2354244A1 (de)	2010-02-04	2011-08-10	Stichting Top Institute Food and Nutrition	MBL2 als Marker für die leberspezifische Insulinresistenz
TWI518325B (zh)	2010-02-04	2016-01-21	自治醫科大學	對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
EP2354245A1 (de)	2010-02-04	2011-08-10	Stichting Top Institute Food and Nutrition	MBL2 als Marker für die hepatische PPAR-Aktivität
EP2542582A4 (de)	2010-03-02	2013-12-04	Abbvie Inc	Therapeutische dll4-bindende proteine
US9616120B2 (en) *	2010-03-04	2017-04-11	Vet Therapeutics, Inc.	Monoclonal antibodies directed to CD20
CA2791866A1 (en) *	2010-03-04	2011-09-09	Vet Therapeutics, Inc.	Monoclonal antibodies directed to cd52
US20130004519A1 (en)	2010-03-05	2013-01-03	Ruth Chiquet-Ehrismann	Smoci, tenascin-c and brain cancers
WO2011119484A1 (en)	2010-03-23	2011-09-29	Iogenetics, Llc	Bioinformatic processes for determination of peptide binding
TR201903279T4 (tr)	2010-03-25	2019-03-21	Ucb Biopharma Sprl	Disülfür stabilize edilmiş DVD-IG molekülleri.
GB201005064D0 (en)	2010-03-25	2010-05-12	Ucb Pharma Sa	Biological products
CA2796339C (en)	2010-04-15	2020-03-31	Abbott Laboratories	Amyloid-beta binding proteins
US11225655B2 (en)	2010-04-16	2022-01-18	Nuevolution A/S	Bi-functional complexes and methods for making and using such complexes
EP2561076A1 (de)	2010-04-19	2013-02-27	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Modulation von xrn1
EP2380909A1 (de)	2010-04-26	2011-10-26	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	An Brustkrebs beteiligtes Protein PTK-7
EP2564200B8 (de)	2010-04-27	2019-10-02	The Regents of The University of California	Krebsbiomarker und anwendungsverfahren dafür
PL2571531T3 (pl)	2010-04-30	2016-12-30		Kompozycje stabilizowanych domen fibronektyny, sposoby i zastosowania
PT2563813E (pt)	2010-04-30	2015-11-26	Alexion Pharma Inc	Anticorpos anti-c5a e métodos para utilização dos anticorpos
US20110293629A1 (en)	2010-05-14	2011-12-01	Bastid Jeremy	Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
KR101539684B1 (ko)	2010-05-14	2015-07-27	애브비 인코포레이티드	Ｉｌ－１ 결합 단백질
MX2012014080A (es)	2010-06-03	2013-05-01	Abbvie Biotechnology Ltd	Usos y composiciones para el tratamiento de hidradenitis superativa (hs).
WO2012047324A2 (en)	2010-06-10	2012-04-12	President And Fellows Of Harvard College	Systems and methods for amplification and phage display
US20130089538A1 (en)	2010-06-10	2013-04-11	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute forBiomedical Researh	Treating cancer by modulating mammalian sterile 20-like kinase 3
BR112012032206A2 (pt)	2010-06-16	2016-10-04	Abbvie Inc	comparações de amostras de proteínas
PL2480676T3 (pl)	2010-06-22	2016-10-31		Mysz wykazująca ekspresję hybrydowego łańcucha lekkiego immunoglobuliny
US20120009196A1 (en)	2010-07-08	2012-01-12	Abbott Laboratories	Monoclonal antibodies against hepatitis c virus core protein
MX343298B (es)	2010-07-09	2016-11-01	Crucell Holland Bv	Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
CN103097418A (zh)	2010-07-09	2013-05-08	霍夫曼-拉罗奇有限公司	抗神经毡蛋白抗体及使用方法
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
KR102318383B1 (ko)	2010-07-16	2021-10-27	아디맵 엘엘씨	항체 라이브러리
CN103119062A (zh)	2010-07-16	2013-05-22	埃博灵克斯股份有限公司	修饰的单结构域抗原结合分子及其应用
EP2601609B1 (de)	2010-08-02	2017-05-17	Population Bio, Inc.	Zusammensetzungen und verfahren zur erkennung der verursachenden mutationen in genetischen erkrankungen
ES2667100T3 (es)	2010-08-02	2018-05-09	Macrogenics, Inc.	Diacuerpos covalentes y sus usos
NZ607480A (en)	2010-08-03	2014-10-31	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
EP2420250A1 (de)	2010-08-13	2012-02-22	Universitätsklinikum Münster	Anti-Syndecan-4-Antikörper
JP6147665B2 (ja)	2010-08-14	2017-06-14	アッヴィ・インコーポレイテッド	アミロイドベータ結合タンパク質
HUE031695T2 (en)	2010-08-17	2017-07-28	Stichting Katholieke Univ	New method for diagnosing Q-fever using a cellular immunological test
HUE058226T2 (hu)	2010-08-19	2022-07-28	Zoetis Belgium S A	NGF elleni antitestek és alkalmazásuk
GB201014033D0 (en)	2010-08-20	2010-10-06	Ucb Pharma Sa	Biological products
PH12013500337A1 (en)	2010-08-26	2017-08-23	Abbvie Inc	Dual variable domain immunoglobulins and uses thereof
US20130224191A1 (en)	2010-08-27	2013-08-29	Robert A. Stull	Notum protein modulators and methods of use
CN106620693A (zh)	2010-09-03	2017-05-10	艾伯维施特姆森特克斯有限责任公司	新型调节剂及使用方法
US20130171159A1 (en)	2010-09-10	2013-07-04	Brian Arthur Hemmings	Phosphorylated twist1 and metastasis
EP2618904A1 (de)	2010-09-20	2013-07-31	AbbVie Inc.	Reinigung von antikörpern mit simulierter wanderbett-chromatografie
RU2013118307A (ru)	2010-09-21	2014-10-27	Стихтинг Катхолике Юниверситейт	Новый способ диагностики белезни лайма с использованием теста клеточного иммунного ответа
WO2012044921A1 (en)	2010-10-01	2012-04-05	St. Jude Children's Research Hospital	Methods and compositions for typing molecular subgroups of medulloblastoma
WO2012052391A1 (en)	2010-10-19	2012-04-26	Glaxo Group Limited	Polypeptide with jmjd3 catalytic activity
SG10202100921YA (en)	2010-10-27	2021-03-30	Univ New York State Res Found	Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
EP2640738A1 (de)	2010-11-15	2013-09-25	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Antimykotische wirkstoffe
WO2012068463A2 (en)	2010-11-18	2012-05-24	Beth Israel Deaconess Medicall Center, Inc.	Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
AU2011338425A1 (en)	2010-12-08	2013-05-02	Stemcentrx, Inc.	Novel modulators and methods of use
EP2465928A1 (de)	2010-12-16	2012-06-20	Academisch Medisch Centrum bij de Universiteit van Amsterdam	Behandlung von Th17-vermittelten Krankheiten
EP2655417A2 (de)	2010-12-21	2013-10-30	AbbVie Inc.	Il-1 alpha- und -beta-bispezifische immunglobuline mit zweifacher variabler domäne und ihre verwendung
TW201307388A (zh)	2010-12-21	2013-02-16	Abbott Lab	Ｉｌ－１結合蛋白
WO2012088381A2 (en)	2010-12-22	2012-06-28	President And Fellows Of Harvard College	Continuous directed evolution
CN103429261A (zh)	2010-12-22	2013-12-04	塞法隆澳大利亚股份有限公司	半寿期改进的修饰抗体
US20140038842A1 (en)	2010-12-28	2014-02-06	Xoma Technology	Cell surface display using pdz domains
EP2658869B1 (de)	2010-12-30	2019-06-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Antigenbindende formate zur verwendung in therapeutischen behandlungen oder diagnosetests
GB201100282D0 (en)	2011-01-07	2011-02-23	Ucb Pharma Sa	Biological methods
US10208349B2 (en)	2011-01-07	2019-02-19	Ucb Biopharma Sprl	Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
PH12013501435B1 (en)	2011-01-14	2019-02-01	UCB Biopharma SRL	Antibody molecules which bind il-17a and il-17f
BR112013018905B1 (pt)	2011-01-24	2021-07-13	Abbvie Biotechnology Ltd	Dispositivos de injeção automática que têm superfícies de pega sobremoldadas.
US9540443B2 (en)	2011-01-26	2017-01-10	Kolltan Pharmaceuticals, Inc.	Anti-kit antibodies
WO2012109238A2 (en)	2011-02-07	2012-08-16	President And Fellows Of Harvard College	Methods for increasing immune responses using agents that directly bind to and activate ire-1
SA112330278B1 (ar)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	مواد ضابطة جديدة وطرق للاستخدام
EP2680925B1 (de)	2011-03-02	2019-11-20	Berg LLC	Interrogatorische zellbasierte assays und verwendung derselben
WO2012122219A2 (en)	2011-03-07	2012-09-13	University Of Louisville Research Foundation	Predictive marker of dnmt1 inhibitor therapeutic efficacy and methods of using the marker
WO2012125735A1 (en)	2011-03-15	2012-09-20	Abott Laboratories	An integrated approach to the isolation and purification of antibodies
EP2689250A1 (de)	2011-03-23	2014-01-29	AbbVie Inc.	Verfahren und systeme zur analyse von proteinproben
AU2012237287B2 (en)	2011-03-30	2016-09-08	Ablynx Nv	Methods of treating immune disorders with single domain antibodies against TNF-alpha
WO2012134813A1 (en)	2011-03-31	2012-10-04	St. Jude Children's Research Hospital	Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia
AU2012239961A1 (en)	2011-04-08	2013-10-24	Biogen Ma Inc.	Biomarkers predictive of therapeutic responsiveness to IFNbeta and uses thereof
WO2012142164A1 (en)	2011-04-12	2012-10-18	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
WO2012145493A1 (en)	2011-04-20	2012-10-26	Amplimmune, Inc.	Antibodies and other molecules that bind b7-h1 and pd-1
JP6145088B2 (ja)	2011-05-21	2017-06-07	マクロジェニクス，インコーポレーテッド	脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用
EP2714084B1 (de)	2011-06-02	2019-05-22	Dyax Corp.	Fc-REZEPTOR-BINDENDE PROTEINE
CN108424451B (zh)	2011-06-03	2022-09-09	佐马技术有限公司	对TGF-β具有特异性的抗体
WO2012168259A1 (en)	2011-06-06	2012-12-13	Novartis Forschungsstiftung, Zweigniederlassung	Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer
WO2012170742A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Treatment and prevention of cancer with hmgb1 antagonists
WO2012170740A2 (en)	2011-06-07	2012-12-13	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
ES2664972T3 (es)	2011-06-10	2018-04-24	Medimmune Limited	Moléculas de unión anti-Psl de Pseudomonas y usos de las mismas
WO2013001369A2 (en)	2011-06-28	2013-01-03	Oxford Biotherapeutics Ltd.	Therapeutic and diagnostic target
SMT201700447T1 (it)	2011-06-28	2017-11-15	Oxford Biotherapeutics Ltd	Anticorpi nei confronti della adp-ribosil ciclasi 2
WO2013009521A2 (en)	2011-07-13	2013-01-17	Abbvie Inc.	Methods and compositions for treating asthma using anti-il-13 antibodies
GB201112056D0 (en)	2011-07-14	2011-08-31	Univ Leuven Kath	Antibodies
CA2853829C (en)	2011-07-22	2023-09-26	President And Fellows Of Harvard College	Evaluation and improvement of nuclease cleavage specificity
AU2012296613B2 (en)	2011-08-15	2016-05-12	Amplimmune, Inc.	Anti-B7-H4 antibodies and their uses
SG2014012728A (en)	2011-08-23	2014-06-27	Foundation Medicine Inc	Novel kif5b-ret fusion molecules and uses thereof
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
WO2013034579A1 (en)	2011-09-05	2013-03-14	Rheinische Friedrich-Wilhelms-Universität Bonn	Biosynthetic gene cluster for the production of peptide/protein analogues
ES2908046T3 (es)	2011-09-09	2022-04-27	Medimmune Ltd	Anticuerpos anti-siglec-15 y usos de los mismos.
US10093705B2 (en)	2011-09-13	2018-10-09	Dana-Farber Cancer Institute, Inc.	Compositions and methods for brown fat induction and activity using FNDC5
EP2771349B1 (de)	2011-09-16	2020-02-26	Iogenetics, LLC.	Bioinformatikverfahren zur bestimmung von peptidbindungen
US10221454B2 (en)	2011-10-10	2019-03-05	The Hospital For Sick Children	Methods and compositions for screening and treating developmental disorders
WO2013056178A2 (en)	2011-10-14	2013-04-18	Foundation Medicine, Inc.	Novel estrogen receptor mutations and uses thereof
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
BR112014009799A2 (pt)	2011-10-24	2017-06-13	Abbvie Inc	imunoligantes dirigidos conra tnf
SG11201401791WA (en)	2011-10-24	2014-08-28	Abbvie Inc	Immunobinders directed against sclerostin
US10598653B2 (en)	2011-11-01	2020-03-24	Bionomics Inc.	Methods of blocking cancer stem cell growth
AU2012332587B2 (en)	2011-11-01	2017-02-23	Bionomics, Inc.	Antibodies and methods of treating cancer
AU2012332590B2 (en)	2011-11-01	2016-10-20	Bionomics, Inc.	Anti-GPR49 antibodies
WO2013067060A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Anti-gpr49 antibodies
US10527526B2 (en)	2011-11-03	2020-01-07	Tripath Imaging, Inc.	Methods and compositions for preparing samples for immunostaining
WO2013067451A2 (en)	2011-11-04	2013-05-10	Population Diagnostics Inc.	Methods and compositions for diagnosing, prognosing, and treating neurological conditions
AU2012336028A1 (en)	2011-11-07	2014-06-26	Medimmune, Llc	Combination therapies using anti- Pseudomonas Psl and PcrV binding molecules
US20140314787A1 (en)	2011-11-08	2014-10-23	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute	Treatment for neurodegenerative diseases
WO2013068432A1 (en)	2011-11-08	2013-05-16	Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research	Early diagnostic of neurodegenerative diseases
CN104271599A (zh)	2011-11-08	2015-01-07	辉瑞公司	使用抗m-csf抗体治疗炎性疾病的方法
PL2776466T3 (pl)	2011-11-11	2018-01-31	Ucb Biopharma Sprl	Przeciwciała wiążące albuminę i ich fragmenty wiążące
WO2013080050A2 (en)	2011-11-30	2013-06-06	Universitaetsklinikum Erlangen	Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
EP2791175A2 (de)	2011-12-14	2014-10-22	Abbvie Deutschland GmbH & Co. KG	Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
EP3800200A1 (de)	2011-12-14	2021-04-07	AbbVie Deutschland GmbH & Co. KG	Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
JP6320300B2 (ja)	2011-12-19	2018-05-09	ゾーマ（ユーエス）リミテッドライアビリティカンパニー	座瘡を治療するための方法
EP3527070B1 (de)	2011-12-20	2025-12-03	Regeneron Pharmaceuticals, Inc.	Humanisierte leichtkettige mäuse
WO2013093809A1 (en)	2011-12-23	2013-06-27	Pfizer Inc.	Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CA2861610A1 (en)	2011-12-30	2013-07-04	Abbvie Inc.	Dual specific binding proteins directed against il-13 and/or il-17
US20140363448A1 (en)	2012-01-02	2014-12-11	Novartis Ag	Cdcp1 and breast cancer
GB201201332D0 (en)	2012-01-26	2012-03-14	Imp Innovations Ltd	Method
US20130330347A1 (en)	2012-01-27	2013-12-12	Abbvie Inc.	Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
EP2812452B1 (de)	2012-02-09	2020-05-27	Population Bio, Inc.	Verfahren und zusammensetzungen zum screening und zur behandlung von entwicklungsstörungen
JP6602012B2 (ja)	2012-02-10	2019-11-06	シアトルジェネティクスインコーポレーテッド	Ｃｄ３０＋癌の検出と治療
SI2814842T1 (sl)	2012-02-15	2018-10-30	Novo Nordisk A/S	Protitelesa, ki vežejo peptidoglikal prepoznan protein 1
LT2814844T (lt)	2012-02-15	2017-10-25	Novo Nordisk A/S	Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
US9550830B2 (en)	2012-02-15	2017-01-24	Novo Nordisk A/S	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
GB201203051D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
GB201203071D0 (en)	2012-02-22	2012-04-04	Ucb Pharma Sa	Biological products
EP3093294A1 (de)	2012-02-24	2016-11-16	Stemcentrx, Inc.	Dll3-antikörper und verfahren zur verwendung
AU2013229786B2 (en)	2012-03-08	2017-06-22	Halozyme, Inc.	Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
US20140087362A1 (en)	2012-03-16	2014-03-27	Aladar A. Szalay	Methods for assessing effectiveness and monitoring oncolytic virus treatment
US9421250B2 (en)	2012-03-23	2016-08-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pathogenic phlebovirus isolates and compositions and methods of use
US20150266961A1 (en)	2012-03-29	2015-09-24	Novartis Forschungsstiftung, Zweigniederlassung, Fridrich Miescher Institute	Inhibition of interleukin-8 and/or its receptor cxcr1 in the treatment of her2/her3-overexpressing breast cancer
EA038600B1 (ru)	2012-04-02	2021-09-21	Берг Ллк	Основанные на клетках перекрестные анализы и их применение
WO2013151649A1 (en)	2012-04-04	2013-10-10	Sialix Inc	Glycan-interacting compounds
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
WO2013158275A1 (en)	2012-04-20	2013-10-24	Abbvie Inc.	Cell culture methods to reduce acidic species
ES2740749T3 (es)	2012-04-20	2020-02-06	Merus Nv	Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
US9150645B2 (en)	2012-04-20	2015-10-06	Abbvie, Inc.	Cell culture methods to reduce acidic species
US9796780B2 (en)	2012-05-14	2017-10-24	Biogen Ma Inc.	LINGO-2 antagonists for treatment of conditions involving motor neurons
ES2766836T3 (es)	2012-05-15	2020-06-15	Eisai Inc	Métodos para el tratamiento de cáncer gástrico
TW201348247A (zh)	2012-05-21	2013-12-01	Abbvie Inc	利用蛋白質ａ親和性層析之非人類抗體之新穎純化
WO2013176754A1 (en)	2012-05-24	2013-11-28	Abbvie Inc.	Novel purification of antibodies using hydrophobic interaction chromatography
EP2859018B1 (de)	2012-06-06	2021-09-22	Zoetis Services LLC	Anti-ngf-antikörper für hunde und verfahren dafür
WO2014001557A1 (en)	2012-06-28	2014-01-03	Ucb Pharma S.A.	A method for identifying compounds of therapeutic interest
EP2866831A1 (de)	2012-06-29	2015-05-06	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Behandlung von krankheiten durch modulation einer spezifischen isoform von mkl1
EP2870242A1 (de)	2012-07-05	2015-05-13	Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research	Neue behandlung für neurodegenerative erkrankungen
EP2869818A1 (de)	2012-07-06	2015-05-13	Novartis AG	Kombination aus einem phosphinositid-3-kinase-hemmer und einem hemmer der il-8-/cxcr-interaktion
TW201402608A (zh)	2012-07-12	2014-01-16	Abbvie Inc	Ｉｌ－１結合蛋白質
GB201213652D0 (en)	2012-08-01	2012-09-12	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
ES3012536T3 (en)	2012-08-03	2025-04-09	Dana Farber Cancer Inst Inc	Antibody against repulsive guidance molecule b (rgmb)
US9737493B2 (en)	2012-09-07	2017-08-22	University Of Louisville Research Foundation, Inc.	Compositions and methods for modulating DNMT1 inhibitor activity
EP2895621B1 (de)	2012-09-14	2020-10-21	Population Bio, Inc.	Verfahren und zusammensetzungen zur diagnose, prognose und behandlung neurologischer erkrankungen
CA2922005A1 (en)	2012-09-27	2014-04-03	Population Diagnostics, Inc.	Methods and compositions for screening and treating developmental disorders
EP2904106A4 (de)	2012-10-01	2016-05-11	Univ Pennsylvania	Zusammensetzungen und verfahren zum anzielung von stromazellen zur behandlung von krebs
US20150238602A1 (en)	2012-10-09	2015-08-27	Biogen Idec Ma Inc.	Combination therapies and uses for treatment of demyelinating disorders
CN104853776B (zh)	2012-10-12	2021-04-09	布里格姆及妇女医院股份有限公司	免疫应答的增强
TW201811825A (zh)	2012-11-01	2018-04-01	美商艾伯維有限公司	抗-ｖｅｇｆ／ｄｌｌ４雙重可變區域免疫球蛋白及其用途
US20150291953A1 (en) *	2012-11-02	2015-10-15	Enzymatics Inc.	Methods and kits for nucleic acid sample preparation for sequencing
EP4223770A3 (de)	2012-11-05	2023-10-18	Foundation Medicine, Inc.	Neuartige fusionsmoleküle und verwendungen davon
HK1214830A1 (zh)	2012-11-05	2016-08-05	Foundation Medicine, Inc.	新型ntrk1融合分子及其应用
WO2014074942A1 (en)	2012-11-08	2014-05-15	Illumina, Inc.	Risk variants of alzheimer's disease
CN104903349B (zh)	2012-11-08	2018-10-19	十一生物治疗股份有限公司	Il-6拮抗剂及其应用
SI2928923T1 (sl)	2012-12-10	2020-03-31	Biogen Ma Inc.	Protitelesa proti antigenu 2 dendritičnih celic v krvi in njihova uporaba
US9790277B2 (en)	2012-12-21	2017-10-17	The Johns Hopkins University	Anti-H7CR antibodies
WO2014100542A1 (en)	2012-12-21	2014-06-26	Abbvie, Inc.	High-throughput antibody humanization
GB201223276D0 (en)	2012-12-21	2013-02-06	Ucb Pharma Sa	Antibodies and methods of producing same
AU2013202668B2 (en)	2012-12-24	2014-12-18	Adelaide Research & Innovation Pty Ltd	Inhibition of cancer growth and metastasis
US10717965B2 (en)	2013-01-10	2020-07-21	Gloriana Therapeutics, Inc.	Mammalian cell culture-produced neublastin antibodies
AU2014207342C1 (en)	2013-01-18	2019-04-04	Foundation Medicine, Inc.	Methods of treating cholangiocarcinoma
GB201302447D0 (en)	2013-02-12	2013-03-27	Oxford Biotherapeutics Ltd	Therapeutic and diagnostic target
SMT201900339T1 (it)	2013-02-22	2019-07-11	Medimmune Ltd	Coniugati anticorpo anti-dll3/pbd e loro usi
WO2014142646A1 (en)	2013-03-13	2014-09-18	Stichting Katholieke Universiteit	Q-fever diagnostic
CN113549148B (zh)	2013-03-14	2025-11-21	雅培制药有限公司	Hcv核心脂质结合结构域单克隆抗体
US9790478B2 (en)	2013-03-14	2017-10-17	Abbott Laboratories	HCV NS3 recombinant antigens and mutants thereof for improved antibody detection
WO2014142882A1 (en)	2013-03-14	2014-09-18	Abbvie Inc.	Protein purification using displacement chromatography
EP2970443A4 (de)	2013-03-14	2017-01-11	Parkash S. Gill	Krebsbehandlung unter verwendung von antikörpern zur bindung von grp78 an die zelloberfläche
JP6505076B2 (ja)	2013-03-14	2019-04-24	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	Ｈｃｖ抗原−抗体組み合わせアッセイおよびこれに使用するための方法および組成物
AU2013384204B2 (en)	2013-03-14	2017-03-16	Abbvie Inc.	Low acidic species compositions and methods for producing and using the same
CA2899449A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	Low acidic species compositions and methods for producing the same using displacement chromatography
EP4079760A3 (de)	2013-03-15	2023-01-25	Sanofi Pasteur Inc.	Antikörper gegen clostridium-difficile-toxine und verfahren zur verwendung davon
HK1219044A1 (zh)	2013-03-15	2017-03-24	艾伯维德国有限责任两合公司	抗egfr抗体药物偶联物制剂
CA2904448A1 (en)	2013-03-15	2014-09-18	Tariq Ghayur	Dual specific binding proteins directed against il-1.beta. and/or il-17
US9469686B2 (en)	2013-03-15	2016-10-18	Abbott Laboratories	Anti-GP73 monoclonal antibodies and methods of obtaining the same
MX2015012562A (es)	2013-03-15	2016-06-21	Abbvie Inc	Purificacion de conjugados anticuerpo-farmaco (cafs).
KR20150128796A (ko)	2013-03-15	2015-11-18	바이오젠 엠에이 인코포레이티드	항-알파 v 베타 5개 항체를 이용한 급성 신장 손상의 치료 및 예방
US9499621B2 (en)	2013-04-08	2016-11-22	Cytodyn, Inc.	Felinized antibodies and methods of treating retroviral infections in felines
EP2992333A1 (de)	2013-05-02	2016-03-09	Stichting Katholieke Universiteit	Personalisierte medizin
SG10201913751RA (en)	2013-05-06	2020-03-30	Scholar Rock Inc	Compositions and methods for growth factor modulation
CA2911600C (en)	2013-05-17	2025-02-04	Centre National De La Recherche Scientifique (Cnrs)	Antibodies against CXCL1, CXCL7 and CXCL8 and their applications
AU2014268298B2 (en)	2013-05-24	2019-01-17	Medlmmune, Llc	Anti-B7-H5 antibodies and their uses
JP6824735B2 (ja)	2013-06-06	2021-02-03	ピエール、ファーブル、メディカマン	抗Ｃ１０ｏｒｆ５４抗体およびその使用方法
EP3004877A4 (de)	2013-06-06	2017-04-19	Dana-Farber Cancer Institute, Inc.	Zusammensetzungen und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
WO2014197885A2 (en)	2013-06-07	2014-12-11	Duke University	Inhibitors of complement factor h
WO2015017529A2 (en)	2013-07-31	2015-02-05	Dana-Farber Cancer Institute, Inc.	Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
ES2761587T3 (es)	2013-08-07	2020-05-20	Friedrich Miescher Institute For Biomedical Res	Nuevo método de cribado para el tratamiento de la ataxia de Friedreich
US9163284B2 (en)	2013-08-09	2015-10-20	President And Fellows Of Harvard College	Methods for identifying a target site of a Cas9 nuclease
PL3036320T5 (pl)	2013-08-19	2024-06-10	Biogen Ma Inc.	Kontrola glikozylacji białka poprzez parametry procesu suplementacji pożywki hodowlanej i hodowli komórkowej
AU2014332442B2 (en)	2013-08-26	2019-12-19	Biontech Research And Development, Inc.	Nucleic acids encoding human antibodies to Sialyl-Lewis
WO2015031698A1 (en)	2013-08-28	2015-03-05	Stem Centrx, Inc.	Site-specific antibody conjugation methods and compositions
CA2922529A1 (en)	2013-08-28	2015-03-05	Stemcentrx, Inc.	Novel sez6 modulators and methods of use
US9340799B2 (en)	2013-09-06	2016-05-17	President And Fellows Of Harvard College	MRNA-sensing switchable gRNAs
EA201600252A1 (ru)	2013-09-12	2017-05-31	Галозим, Инк.	Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
WO2015048331A1 (en)	2013-09-25	2015-04-02	Cornell University	Compounds for inducing anti-tumor immunity and methods thereof
US10611794B2 (en)	2013-09-25	2020-04-07	Bioverativ Therapeutics Inc.	On-column viral inactivation methods
US10570204B2 (en)	2013-09-26	2020-02-25	The Medical College Of Wisconsin, Inc.	Methods for treating hematologic cancers
WO2015057939A1 (en)	2013-10-18	2015-04-23	Biogen Idec Ma Inc.	Anti-s1p4 antibodies and uses thereof
EP3063317B1 (de)	2013-10-28	2020-06-03	DOTS Technology Corp.	Allergennachweis
WO2015066190A1 (en)	2013-10-29	2015-05-07	President And Fellows Of Harvard College	Methods and compositions for inhibting oxidative stress
EP2871189A1 (de)	2013-11-07	2015-05-13	Institut Pasteur	Hochaffiner, monoklonaler Anti-Strep-Tag-Antikörper
US20160272674A1 (en)	2013-11-07	2016-09-22	Abbvie Inc.	Isolation and purification of antibodies
DK3511422T3 (da)	2013-11-12	2023-02-06	Population Bio Inc	Fremgangsmåder og sammensætninger til diagnosticering, prognose og behandling af endometriose
KR102283408B1 (ko)	2013-11-15	2021-07-29	앵스티띠 파스퇴르	플라스모듐 팔시파룸 아르테미시닌 내성의 분자 마커
US8986694B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Targeting human nav1.7 variants for treatment of pain
US9045545B1 (en)	2014-07-15	2015-06-02	Kymab Limited	Precision medicine by targeting PD-L1 variants for treatment of cancer
US9914769B2 (en)	2014-07-15	2018-03-13	Kymab Limited	Precision medicine for cholesterol treatment
US8992927B1 (en)	2014-07-15	2015-03-31	Kymab Limited	Targeting human NAV1.7 variants for treatment of pain
US9067998B1 (en)	2014-07-15	2015-06-30	Kymab Limited	Targeting PD-1 variants for treatment of cancer
BR112016013187A2 (pt)	2013-12-19	2017-09-26	Novartis Ag	receptores de antígenos quiméricos de mesotelina humanos e usos dos mesmos
US11708411B2 (en)	2013-12-20	2023-07-25	Wake Forest University Health Sciences	Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
EP3083933B1 (de)	2013-12-20	2026-01-21	Biogen MA Inc.	Verwendung von perfusionssaatkulturen zur verbesserung der biopharmazeutischen fed-batch-produktionskapazitäten und der produktqualität
EP2960252A1 (de)	2014-06-26	2015-12-30	Institut Pasteur	Phospholipase zur Behandlung von Immunosuppression
AU2014372309C1 (en)	2013-12-24	2017-12-14	Janssen Pharmaceutica Nv	Anti-VISTA antibodies and fragments
WO2015103438A2 (en)	2014-01-02	2015-07-09	Genelux Corporation	Oncolytic virus adjunct therapy with agents that increase virus infectivity
CA2935804A1 (en)	2014-01-14	2015-07-23	Dana-Farber Cancer Institute, Inc.	Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
US10179911B2 (en)	2014-01-20	2019-01-15	President And Fellows Of Harvard College	Negative selection and stringency modulation in continuous evolution systems
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
AU2015217572B2 (en)	2014-02-11	2020-10-15	Visterra, Inc.	Antibody moleules to dengue virus and uses thereof
KR20170008202A (ko)	2014-02-21	2017-01-23	애브비 스템센트알엑스 엘엘씨	흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
PH12016501545B1 (en)	2014-03-14	2023-12-06	Immutep Sas	Antibody molecules to lag-3 and uses thereof
US9738702B2 (en)	2014-03-14	2017-08-22	Janssen Biotech, Inc.	Antibodies with improved half-life in ferrets
WO2015148515A1 (en)	2014-03-24	2015-10-01	Biogen Ma Inc.	Methods for overcoming glutamine deprivation during mammalian cell culture
EP3125938A4 (de)	2014-03-31	2017-08-23	The Johns Hopkins University	Verwendung von bakterien, bakteriellen produkten und anderen immunregulatorischen einheiten in kombination mit anti-ctla-4- und/oder anti-pd-1-antikörpern zur behandlung von festen tumormalignomen
MX2016012873A (es)	2014-04-04	2017-03-07	Bionomics Inc	Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
IL248511B (en)	2014-05-13	2022-07-01	Bavarian Nordic As	Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
EP3142700B1 (de)	2014-05-16	2021-03-03	Medimmune, LLC	Moleküle mit veränderter neonater fc-rezeptorbindung mit verbesserten therapeutischen und diagnostischen eigenschaften
MX377844B (es)	2014-05-28	2025-03-11	Agenus Inc	Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso.
GB201409558D0 (en)	2014-05-29	2014-07-16	Ucb Biopharma Sprl	Method
MX355107B (es)	2014-06-03	2018-04-04	Xbiotech Inc	Composiciones y metodos para tratar y prevenir infecciones por staphylococcus aureus.
KR102614642B1 (ko)	2014-06-04	2023-12-19	바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드	강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
US20170137824A1 (en)	2014-06-13	2017-05-18	Indranil BANERJEE	New treatment against influenza virus
WO2015198202A1 (en)	2014-06-23	2015-12-30	Friedrich Miescher Institute For Biomedical Research	Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
GB201411320D0 (en)	2014-06-25	2014-08-06	Ucb Biopharma Sprl	Antibody construct
WO2016001830A1 (en)	2014-07-01	2016-01-07	Friedrich Miescher Institute For Biomedical Research	Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
US9139648B1 (en)	2014-07-15	2015-09-22	Kymab Limited	Precision medicine by targeting human NAV1.9 variants for treatment of pain
GB201412659D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
GB201412658D0 (en)	2014-07-16	2014-08-27	Ucb Biopharma Sprl	Molecules
WO2016009086A1 (en)	2014-07-17	2016-01-21	Novo Nordisk A/S	Site directed mutagenesis of trem-1 antibodies for decreasing viscosity
US9777061B2 (en)	2014-07-21	2017-10-03	Novartis Ag	Treatment of cancer using a CD33 chimeric antigen receptor
EP3511413B1 (de)	2014-07-25	2022-09-07	Theravectys	Lentivirale vektoren zur regulierten expression eines chimären antigenrezeptormoleküls
EP3177718B1 (de)	2014-07-30	2022-03-16	President and Fellows of Harvard College	Cas9-proteine mit ligandenabhängigen inteinen
JP6919118B2 (ja)	2014-08-14	2021-08-18	ノバルティスアーゲー	ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
TW202140557A (zh)	2014-08-19	2021-11-01	瑞士商諾華公司	使用cd123嵌合抗原受體治療癌症
WO2016033555A1 (en)	2014-08-28	2016-03-03	Halozyme, Inc.	Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor
GB2558326B (en)	2014-09-05	2021-01-20	Population Bio Inc	Methods and compositions for inhibiting and treating neurological conditions
CN107206071A (zh)	2014-09-13	2017-09-26	诺华股份有限公司	Alk抑制剂的联合疗法
EP3194444B1 (de)	2014-09-16	2019-07-10	Symphogen A/S	Anti-met-antikörper und zusammensetzungen
US20170298360A1 (en)	2014-09-24	2017-10-19	Friedrich Miescher Institute For Biomedical Research	Lats and breast cancer
JP6875275B2 (ja)	2014-09-30	2021-05-19	ドイチェスクレブスフォルシュングスツェントルムシュティフトゥングデスエッフェントリッヒェンレヒツ	Ｌ１ｃａｍ（ｃｄ１７）と結合する抗体などの結合分子
KR102594117B1 (ko)	2014-10-01	2023-10-26	메디뮨 리미티드	티카그렐로에 대한 항체 및 이의 사용 방법
AU2015327868A1 (en)	2014-10-03	2017-04-20	Novartis Ag	Combination therapies
CA2964367C (en)	2014-10-14	2024-01-30	Novartis Ag	Antibody molecules to pd-l1 and uses thereof
MA41685A (fr)	2014-10-17	2017-08-22	Biogen Ma Inc	Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
US10920208B2 (en)	2014-10-22	2021-02-16	President And Fellows Of Harvard College	Evolution of proteases
MA40864A (fr)	2014-10-31	2017-09-05	Biogen Ma Inc	Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
EP3215527B1 (de)	2014-11-05	2025-01-08	Annexon, Inc.	Humanisierte anti-komplementfaktor-c1q-antikörper und verwendungen davon
PE20171107A1 (es)	2014-11-07	2017-08-07	Eleven Biotherapeutics Inc	Anticuerpos mejorados contra il-6
WO2016073894A1 (en)	2014-11-07	2016-05-12	Eleven Biotherapeutics, Inc.	Therapeutic agents with increased ocular retention
US20170306046A1 (en)	2014-11-12	2017-10-26	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
US9879087B2 (en)	2014-11-12	2018-01-30	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
WO2016081835A2 (en)	2014-11-21	2016-05-26	University Of Maryland, Baltimore	Targeted structure-specific particulate delivery systems
WO2016090323A1 (en)	2014-12-05	2016-06-09	Prelude, Inc.	Dcis recurrence and invasive breast cancer
US11220545B2 (en)	2014-12-08	2022-01-11	Dana-Farber Cancer Institute, Inc.	Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
SI3333191T1 (sl)	2014-12-11	2021-03-31	Pierre Fabre Medicament	Proti C10ORF54 protitelesa in uporaba le-teh
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
WO2016100882A1 (en)	2014-12-19	2016-06-23	Novartis Ag	Combination therapies
JP7211703B2 (ja)	2014-12-22	2023-01-24	ザロックフェラーユニバーシティー	抗ｍｅｒｔｋアゴニスト抗体及びその使用
WO2016112270A1 (en)	2015-01-08	2016-07-14	Biogen Ma Inc.	Lingo-1 antagonists and uses for treatment of demyelinating disorders
JP2018507254A (ja)	2015-02-02	2018-03-15	アイツーファーマシューティカルズ，インコーポレーテッド	抗代替軽鎖抗体
CN114504652A (zh)	2015-03-03	2022-05-17	科马布有限公司	抗体、用途和方法
US10711067B2 (en)	2015-03-03	2020-07-14	Xoma (Us) Llc	Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
ES2805206T3 (es)	2015-03-10	2021-02-11	Univ Massachusetts	Enfoque dirigido a GDF6 y a señalización de BMP para la terapia contra el melanoma
EP3273994B1 (de)	2015-03-27	2021-12-01	University of Southern California	Car-t-zelltherapie gegen lhr zur behandlung von soliden tumoren
CN116327915A (zh)	2015-04-03	2023-06-27	佐马技术有限公司	使用TGF-β抑制剂和PD-1抑制剂治疗癌症
US11299729B2 (en)	2015-04-17	2022-04-12	President And Fellows Of Harvard College	Vector-based mutagenesis system
WO2016168755A1 (en)	2015-04-17	2016-10-20	Distributed Bio, Inc.	Method for mass humanization of non-human antibodies
EP3285811A1 (de)	2015-04-21	2018-02-28	Institut Gustave Roussy	Therapeutische verfahren, produkte und zusammensetzungen zur hemmung von znf555
GB201506869D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
GB201506870D0 (en)	2015-04-22	2015-06-03	Ucb Biopharma Sprl	Method
EP3288542B1 (de)	2015-04-29	2021-12-29	University Of South Australia	Zusammensetzungen und verfahren zur verabreichung von antikörpern
US11685773B2 (en)	2015-04-30	2023-06-27	Abcheck S.R.O.	Method for mass humanization of rabbit antibodies
EP3291836A4 (de)	2015-05-06	2018-11-14	Janssen Biotech, Inc.	Bispezifische bindemittel für prostataspezifisches membranantigen (psma) und verwendungen davon
EA201792451A1 (ru)	2015-05-07	2018-05-31	Агенус Инк.	Антитела к ox40 и способы их применения
JP6851322B2 (ja)	2015-05-27	2021-03-31	ユーシービーバイオファルマエスアールエル	神経疾患を治療する方法
HUE048284T2 (hu)	2015-05-29	2020-07-28	Abbvie Inc	Anti-CD40 antitestek és alkalmazásuk
CN107849144B (zh)	2015-05-29	2021-09-17	艾吉纳斯公司	抗-ctla-4抗体及其使用方法
EP3302559B1 (de)	2015-06-04	2022-01-12	University of Southern California	Auf lym-1 und lym-2 abgerichtete car-zellen-immuntherapie
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
GB201510758D0 (en)	2015-06-18	2015-08-05	Ucb Biopharma Sprl	Novel TNFa structure for use in therapy
EP3722314A1 (de)	2015-06-24	2020-10-14	Janssen Pharmaceutica NV	Anti-vista-antikörper und -fragmente
GB201601075D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies molecules
GB201601077D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibody molecule
GB201601073D0 (en)	2016-01-20	2016-03-02	Ucb Biopharma Sprl	Antibodies
WO2017015545A1 (en)	2015-07-22	2017-01-26	President And Fellows Of Harvard College	Evolution of site-specific recombinases
US11524983B2 (en)	2015-07-23	2022-12-13	President And Fellows Of Harvard College	Evolution of Bt toxins
EP4378957A3 (de)	2015-07-29	2024-08-07	Novartis AG	Kombinationstherapien mit antikörpermolekülen gegen pd-1
WO2017019897A1 (en)	2015-07-29	2017-02-02	Novartis Ag	Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da)	2015-07-29	2021-06-28	Immutep Sas	Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019895A1 (en)	2015-07-30	2017-02-02	President And Fellows Of Harvard College	Evolution of talens
AU2016304588A1 (en)	2015-08-06	2018-02-15	Xoma (Us) Llc	Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia
EP3932953A1 (de)	2015-08-28	2022-01-05	F. Hoffmann-La Roche AG	Anti-hypusin-antikörper und verwendungen davon
HK1257840A1 (zh)	2015-09-01	2019-11-01	Agenus Inc.	抗-pd-1抗体及其使用方法
RS66913B1 (sr)	2015-09-15	2025-07-31	Scholar Rock Inc	Anti-pro/latentna antitela miostatina i njihova upotreba
CN109310744A (zh)	2015-09-23	2019-02-05	赛通免疫有限责任公司	用于免疫治疗的flt3定向car细胞
RU2763916C2 (ru)	2015-09-23	2022-01-11	Дженентек, Инк.	Оптимизированные варианты анти-vegf антител
US11207393B2 (en)	2015-10-16	2021-12-28	President And Fellows Of Harvard College	Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
SG10202104041PA (en)	2015-10-23	2021-06-29	Harvard College	Nucleobase editors and uses thereof
EP3368570A1 (de)	2015-10-27	2018-09-05	UCB Biopharma SPRL	Verfahren zur behandlung mit anti-il-17a/f-antikörpern
WO2017072669A1 (en)	2015-10-28	2017-05-04	Friedrich Miescher Institute For Biomedical Research	Tenascin-w and biliary tract cancers
WO2017075329A2 (en)	2015-10-29	2017-05-04	Dana-Farber Cancer Institute, Inc.	Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
CA3004790A1 (en)	2015-11-10	2017-05-18	Visterra, Inc.	Lipopolysaccharide binding antibody-antimicrobial peptide conjugates and uses thereof
CN108463248B (zh)	2015-11-12	2022-10-21	西雅图基因公司	聚糖相互作用化合物及使用方法
HK1254337A1 (zh)	2015-11-25	2019-07-19	Visterra, Inc.	April的抗体分子及其用途
KR102803158B1 (ko)	2015-12-02	2025-05-08	주식회사 에스티큐브앤컴퍼니	Btn1a1에 면역특이적으로 결합하는 항체와 분자 및 그의 치료 용도
EP3383908A1 (de)	2015-12-02	2018-10-10	Stsciences, Inc.	Spezifische antikörper gegen glykosylierten btla (b- und t-lymphozyt-attenuator)
GB201521391D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521383D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl And Ucb Celltech	Method
GB201521389D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Method
GB201521382D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
GB201521393D0 (en)	2015-12-03	2016-01-20	Ucb Biopharma Sprl	Antibodies
WO2017097889A1 (en)	2015-12-10	2017-06-15	Katholieke Universiteit Leuven	Anti adamts13 antibodies and their use for treatment or prevention of haemorrhagic disorders due to ventricular assist device
KR102833068B1 (ko)	2015-12-17	2025-07-14	노파르티스 아게	Pd-1에 대한 항체 분자 및 그의 용도
CA3007421A1 (en)	2015-12-17	2017-06-22	Novartis Ag	Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
EP3400240A2 (de)	2016-01-08	2018-11-14	Scholar Rock, Inc.	Anti-pro/latente myostatin-antikörper und verfahren zur verwendung davon
GB201602413D0 (en)	2016-02-10	2016-03-23	Nascient Ltd	Method
US10899836B2 (en)	2016-02-12	2021-01-26	Janssen Pharmaceutica Nv	Method of identifying anti-VISTA antibodies
MX2018010032A (es)	2016-02-23	2019-03-11	Sesen Bio Inc	Formulaciones de antagonista de il-6 y sus usos.
EP3423488A4 (de)	2016-02-29	2019-11-06	Foundation Medicine, Inc.	Verfahren zur behandlung von krebs
JP6821693B2 (ja)	2016-02-29	2021-01-27	ジェネンテック，インコーポレイテッド	がんのための治療方法及び診断方法
EP3426298A4 (de)	2016-03-10	2019-11-27	Viela Bio, Inc.	Ilt7-bindende moleküle und verfahren zur verwendung davon
KR20180122397A (ko)	2016-03-11	2018-11-12	스칼러 락, 인크.	TGFβ1-결합 이뮤노글로불린 및 그의 용도
WO2017160599A1 (en)	2016-03-14	2017-09-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Use of cd300b antagonists to treat sepsis and septic shock
WO2017161206A1 (en)	2016-03-16	2017-09-21	Halozyme, Inc.	Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CA3017813C (en)	2016-03-17	2021-12-07	Oslo Universitetssykehus Hf	Fusion proteins targeting tumour associated macrophages for treating cancer
WO2017165464A1 (en)	2016-03-21	2017-09-28	Elstar Therapeutics, Inc.	Multispecific and multifunctional molecules and uses thereof
JP2019509322A (ja)	2016-03-22	2019-04-04	バイオノミクスリミテッド	抗ｌｇｒ５モノクローナル抗体の投与
WO2017165665A1 (en)	2016-03-23	2017-09-28	The General Hospital Corporation	Assays and methods for detecting udp-glucose
CN109311986A (zh)	2016-03-25	2019-02-05	威特拉公司	登革热病毒抗体分子的制剂
JP7468992B2 (ja)	2016-03-29	2024-04-16	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ１２及び／又は－２３抗体の増加した間隔投与による乾癬の処置
WO2017175058A1 (en)	2016-04-07	2017-10-12	Janssen Pharmaceutica Nv	Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3439692A4 (de)	2016-04-08	2020-01-22	ITI Health, Inc.	Plectin-1-antikörper und verwendungen davon
WO2017181098A2 (en)	2016-04-15	2017-10-19	Visterra, Inc.	Antibody molecules to zika virus and uses thereof
WO2017205465A2 (en)	2016-05-24	2017-11-30	Griswold Karl Edwin	Antibodies and methods of making same
MX389710B (es)	2016-05-27	2025-03-20	Agenus Inc	Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
BR112018076281A2 (pt)	2016-06-20	2019-03-26	Kymab Limited	imunocitocina, uso de uma imunocitocina, método, composição farmacêutica, método para tratar uma doença proliferativa em um animal, ácido nucleico, vetor, hospedeiro e anticorpo ou fragmento do mesmo
CN110291402B (zh)	2016-06-27	2023-09-01	朱诺治疗学股份有限公司	鉴定肽表位的方法、结合此类表位的分子和相关用途
MA45491A (fr)	2016-06-27	2019-05-01	Juno Therapeutics Inc	Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
AU2017292752B2 (en)	2016-07-06	2023-07-27	Celgene Corporation	Antibodies with low immunogenicity and uses thereof
AU2017292184A1 (en)	2016-07-08	2019-02-07	Staten Biotechnology B.V.	Anti-Apoc3 antibodies and methods of use thereof
AU2017297404A1 (en)	2016-07-13	2019-01-24	Biogen Ma Inc.	Dosage regimens of LINGO-1 antagonists and uses for treatment of demyelinating disorders
AU2017295886C1 (en)	2016-07-15	2024-05-16	Novartis Ag	Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US20200148750A1 (en)	2016-07-21	2020-05-14	Emory University	Ebola Virus Antibodies and Binding Agents Derived Therefrom
EP3487880A1 (de)	2016-07-25	2019-05-29	Biogen MA Inc.	Anti-hspa5(grp78)-antikörper und verwendungen davon
EP3490600A1 (de)	2016-08-01	2019-06-05	Xoma (Us) Llc	Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
KR102777127B1 (ko)	2016-08-02	2025-03-07	비스테라, 인크.	조작된 폴리펩티드 및 그의 용도
EP3494215A1 (de)	2016-08-03	2019-06-12	President and Fellows of Harvard College	Adenosenukleobaseneditoren und verwendungen davon
WO2018027042A1 (en)	2016-08-03	2018-02-08	Bio-Techne Corporation	Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
CN109804066A (zh)	2016-08-09	2019-05-24	哈佛大学的校长及成员们	可编程cas9-重组酶融合蛋白及其用途
WO2018039438A1 (en)	2016-08-24	2018-03-01	President And Fellows Of Harvard College	Incorporation of unnatural amino acids into proteins using base editing
EP3933039A1 (de)	2016-09-15	2022-01-05	ArcherDX, LLC	Verfahren für die zubereitung von nukleinsäureproben
US10683531B2 (en)	2016-09-15	2020-06-16	ArcherDX, Inc.	Methods of nucleic acid sample preparation for analysis of cell-free DNA
AU2017331277B2 (en)	2016-09-23	2024-05-30	Marengo Therapeutics, Inc.	Multispecific antibody molecules comprising lambda and kappa light chains
AU2017335771A1 (en)	2016-09-28	2019-02-28	Musc Foundation For Research Development	Antibodies that bind interleukin-2 and uses thereof
GB201616596D0 (en)	2016-09-29	2016-11-16	Nascient Limited	Epitope and antibodies
WO2018064436A1 (en)	2016-09-30	2018-04-05	Janssen Biotech, Inc.	Safe and effective method of treating psoriasis with anti-il23 specific antibody
JP2019535015A (ja)	2016-10-03	2019-12-05	アボット・ラボラトリーズＡｂｂｏｔｔＬａｂｏｒａｔｏｒｉｅｓ	患者サンプルにおけるｇｆａｐ状況を評価する改善された方法
CN110225927B (zh)	2016-10-07	2024-01-12	诺华股份有限公司	用于治疗癌症的嵌合抗原受体
KR20230133934A (ko)	2016-10-11	2023-09-19	아게누스 인코포레이티드	항-lag-3 항체 및 이의 사용 방법
AU2017342543B2 (en)	2016-10-14	2024-06-27	President And Fellows Of Harvard College	AAV delivery of nucleobase editors
WO2018071576A1 (en)	2016-10-14	2018-04-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Treatment of tumors by inhibition of cd300f
WO2018085359A1 (en)	2016-11-02	2018-05-11	Immunogen, Inc.	Combination treatment with antibody-drug conjugates and parp inhibitors
US11779604B2 (en)	2016-11-03	2023-10-10	Kymab Limited	Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102539159B1 (ko)	2016-11-07	2023-06-02	주식회사 뉴라클사이언스	서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
DE102016121899A1 (de)	2016-11-15	2018-05-17	Immatics Biotechnologies Gmbh	Verfahren zur Herstellung von elektrokompetenten Hefezellen und Verfahren zur Verwendung dieser Zellen
IL323048A (en)	2016-11-16	2025-10-01	Janssen Biotech Inc	Method for treating psoriasis with a specific anti-IL-23 antibody
WO2018094143A1 (en)	2016-11-17	2018-05-24	Siamab Therapeutics, Inc.	Glycan-interacting compounds and methods of use
KR102504605B1 (ko)	2016-12-07	2023-03-02	아게누스 인코포레이티드	항-ctla-4 항체 및 이의 사용 방법
CA3046082A1 (en)	2016-12-07	2018-06-14	Agenus Inc.	Antibodies and methods of use thereof
KR102568559B1 (ko)	2016-12-14	2023-08-18	얀센 바이오테크 인코포레이티드	Cd8a-결합 섬유결합소 iii형 도메인
EP3554561B1 (de)	2016-12-14	2023-06-28	Janssen Biotech, Inc.	Cd137-bindende fibronectin-typ-iii-domänen
EP3554535A4 (de)	2016-12-14	2020-10-21	Janssen Biotech, Inc.	Pd-l1-bindende fibronectin-typ iii-domänen
GB201621635D0 (en)	2016-12-19	2017-02-01	Ucb Biopharma Sprl	Crystal structure
IL315727A (en)	2016-12-23	2024-11-01	Visterra Inc	Binding polypeptides and methods for their preparation
WO2018119359A1 (en)	2016-12-23	2018-06-28	President And Fellows Of Harvard College	Editing of ccr5 receptor gene to protect against hiv infection
PT3565592T (pt)	2017-01-06	2023-05-31	Scholar Rock Inc	Tratamento de doenças metabólicas através da inibição da ativação da miostatina
EP4218817A3 (de)	2017-01-06	2023-09-06	Scholar Rock, Inc.	Verfahren zur behandlung von stoffwechselerkrankungen durch hemmung der myostatinaktivierung
KR20240137126A (ko)	2017-01-06	2024-09-19	스칼러 락, 인크.	이소형-특이적, 콘텍스트-허용성 TGFβ1 억제제 및 그의 용도
CN110312530A (zh)	2017-01-13	2019-10-08	中央研究院	用以治疗心肌梗塞的可重复装载的水胶系统
TWI659751B (zh)	2017-01-13	2019-05-21	中央研究院	用以治療腦部疾病之可重複裝載之改良水膠系統
CA3049449A1 (en)	2017-01-18	2018-07-26	Visterra, Inc.	Antibody molecule-drug conjugates and uses thereof
EP3573658A4 (de)	2017-01-30	2021-07-21	Janssen Biotech, Inc.	Anti-tnf-antikörper, zusammensetzungen und verfahren zur behandlung von aktiver psoriatischer arthritis
US10240205B2 (en)	2017-02-03	2019-03-26	Population Bio, Inc.	Methods for assessing risk of developing a viral disease using a genetic test
WO2018141029A1 (en)	2017-02-06	2018-08-09	Meat & Livestock Australia Limited	Immunostimulating compositions and uses therefore
EP3579871A4 (de)	2017-02-07	2021-07-21	Janssen Biotech, Inc.	Anti-tnf-antikörper, zusammensetzungen und verfahren zur behandlung von aktivem morbus bechterew
WO2018151820A1 (en)	2017-02-16	2018-08-23	Elstar Therapeutics, Inc.	Multifunctional molecules comprising a trimeric ligand and uses thereof
WO2018158719A1 (en)	2017-03-02	2018-09-07	Novartis Ag	Engineered heterodimeric proteins
CA3054939A1 (en)	2017-03-03	2018-09-07	Seattle Genetics, Inc.	Glycan-interacting compounds and methods of use
US11898179B2 (en)	2017-03-09	2024-02-13	President And Fellows Of Harvard College	Suppression of pain by gene editing
CN110662556A (zh)	2017-03-09	2020-01-07	哈佛大学的校长及成员们	癌症疫苗
KR20190127797A (ko)	2017-03-10	2019-11-13	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	시토신에서 구아닌으로의 염기 편집제
IL269458B2 (en)	2017-03-23	2024-02-01	Harvard College	Nucleic base editors that include nucleic acid programmable DNA binding proteins
JP7346300B2 (ja)	2017-03-23	2023-09-19	アボット・ラボラトリーズ	早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼｌ１を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
EP3599843A4 (de)	2017-03-24	2021-01-13	The Regents of the University of California	Proteoglycan-irregularitäten in abnormalen fibroblasten und darauf basierende therapien
AU2018249493A1 (en)	2017-04-03	2019-09-19	Oncxerna Therapeutics, Inc.	Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
JP2020512825A (ja)	2017-04-12	2020-04-30	ファイザー・インク	条件的親和性を有する抗体およびその使用の方法
AU2018253176B2 (en)	2017-04-13	2023-02-02	Agenus Inc.	Anti-CD137 antibodies and methods of use thereof
BR112019021612A2 (pt)	2017-04-15	2020-05-12	Abbott Laboratories	Métodos para auxiliar o diagnóstico hiperagudo e determinação de traumatismo crânioencefálico em um indivíduo humano com o uso de biomarcadores precoces
US12134654B2 (en)	2017-04-19	2024-11-05	Marengo Therapeutics, Inc.	Multispecific molecules and uses thereof
WO2018193427A1 (en)	2017-04-21	2018-10-25	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
CA3059769A1 (en)	2017-04-28	2018-11-01	Elstar Therapeutics, Inc.	Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
US10877038B2 (en)	2017-04-28	2020-12-29	Abbott Laboratories	Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
TW202402800A (zh)	2017-05-01	2024-01-16	美商艾吉納斯公司	抗ｔｉｇｉｔ抗體類和使用彼等之方法
US10865238B1 (en)	2017-05-05	2020-12-15	Duke University	Complement factor H antibodies
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها
WO2018209320A1 (en)	2017-05-12	2018-11-15	President And Fellows Of Harvard College	Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
WO2018215535A1 (en)	2017-05-23	2018-11-29	Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Novel cd73 antibody, preparation and uses thereof
JP7416625B2 (ja)	2017-05-25	2024-01-17	アボット・ラボラトリーズ	早期バイオマーカーを使用する、頭部への損傷を負ったヒト対象又は負った可能性があるヒト対象に対して、イメージングを実施するかどうかの決定の一助となるための方法
AU2018275235B2 (en)	2017-05-30	2024-07-18	Abbott Laboratories	Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers
JP7768666B2 (ja)	2017-05-31	2025-11-12	ストキューブアンドシーオー．，インコーポレイテッド	Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子を用いて癌を治療する方法
JP7369038B2 (ja)	2017-05-31	2023-10-25	ストキューブアンドシーオー．，インコーポレイテッド	Ｂｔｎ１ａ１に免疫特異的に結合する抗体及び分子並びにその治療的使用
JP2020522254A (ja)	2017-05-31	2020-07-30	エルスターセラピューティクス，インコーポレイテッド	骨髄増殖性白血病（ｍｐｌ）タンパク質に結合する多特異性分子およびその使用
CN121248782A (zh)	2017-06-06	2026-01-02	斯特库伯株式会社	使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法
US11572541B2 (en)	2017-06-09	2023-02-07	Providence Health & Services—Oregon	Utilization of CD39 and CD103 for identification of human tumor reactive T cells for treatment of cancer
GB201709379D0 (en)	2017-06-13	2017-07-26	Univ Leuven Kath	Humanised ADAMTS13 binding antibodies
US20190062428A1 (en)	2017-06-19	2019-02-28	Surface Oncology, Inc.	Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
WO2018237173A1 (en)	2017-06-22	2018-12-27	Novartis Ag	Antibody molecules to cd73 and uses thereof
WO2019005817A2 (en)	2017-06-26	2019-01-03	Bio-Techne Corporation	HYBRIDOMIC CLONES, MONOCLONAL ANTIBODIES DIRECTED AGAINST VSIG-4, AND METHODS OF MAKING AND USING SAME
AU2018292618A1 (en)	2017-06-27	2019-12-19	Novartis Ag	Dosage regimens for anti-TIM-3 antibodies and uses thereof
US11618783B2 (en)	2017-06-27	2023-04-04	Neuracle Science Co., Ltd.	Anti-FAM19A5 antibodies and uses thereof
EP3649474A1 (de)	2017-07-03	2020-05-13	Abbott Laboratories	Verbesserte verfahren zur messung von ubiquitin-carboxy-terminalen hydrolase-l1-konzentrationen in blut
US11447809B2 (en)	2017-07-06	2022-09-20	President And Fellows Of Harvard College	Evolution of tRNA synthetases
BR112020000719A2 (pt)	2017-07-11	2020-07-14	Compass Therapeutics Llc	anticorpos agonistas que ligam o cd137 humano e seus usos
BR112020000698A2 (pt)	2017-07-14	2020-07-14	Pfizer Inc.	anticorpos contra madcam
EP3431496A1 (de)	2017-07-19	2019-01-23	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti-isoasp7-amyloid-beta-antikörper und verwendungen davon
AU2018302283B2 (en)	2017-07-20	2025-07-10	Novartis Ag	Dosage regimens of anti-LAG-3 antibodies and uses thereof
WO2019023680A1 (en)	2017-07-28	2019-01-31	President And Fellows Of Harvard College	METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
US12358992B2 (en)	2017-07-28	2025-07-15	Scholar Rock, Inc.	LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
WO2019035938A1 (en)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
EP3684811A2 (de)	2017-08-17	2020-07-29	Massachusetts Institute of Technology	Multispezifitätsbinder von cxc-chemokinen und ihre verwendung
AU2018321405A1 (en)	2017-08-25	2020-03-05	Ipsen Biopharm Ltd.	Evolution of BoNT peptidases
CA3070774A1 (en)	2017-08-25	2019-02-28	Five Prime Therapeutics, Inc.	B7-h4 antibodies and methods of use thereof
US11319532B2 (en)	2017-08-30	2022-05-03	President And Fellows Of Harvard College	High efficiency base editors comprising Gam
US11624130B2 (en)	2017-09-18	2023-04-11	President And Fellows Of Harvard College	Continuous evolution for stabilized proteins
TW201922780A (zh)	2017-09-25	2019-06-16	美商健生生物科技公司	以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
JP2021501566A (ja)	2017-10-02	2021-01-21	ビステラ，インコーポレイテッド	Ｃｄ１３８に対する抗体分子およびその使用
ES2759622T3 (es)	2017-10-02	2020-05-11	Certest Biotec S L	Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
JP2020536115A (ja)	2017-10-04	2020-12-10	オプコファーマシューティカルズ、エルエルシー	癌の個別化療法に関する物品および方法
CN111630069B (zh)	2017-10-13	2024-05-31	勃林格殷格翰国际有限公司	针对Thomsen-nouvelle(Tn)抗原的人抗体
WO2019079347A1 (en)	2017-10-16	2019-04-25	The Broad Institute, Inc.	USES OF BASIC EDITORS ADENOSINE
BR112020007046A2 (pt)	2017-10-19	2020-11-17	Debiopharm International S.A.	produto de combinação para o tratamento do câncer
WO2019077165A1 (en)	2017-10-20	2019-04-25	Institut Curie	DAP10 / 12-BASED CHIMERIC ANTIGENIC RECEPTORS (CAR) ADAPTED FOR RUSH
EP3625263B8 (de)	2017-10-27	2025-05-28	New York University	Anti-galectin-9-antikörper und verwendungen davon
WO2019087115A1 (en)	2017-10-31	2019-05-09	Staten Biotechnology B.V.	Anti-apoc3 antibodies and methods of use thereof
WO2019089753A2 (en)	2017-10-31	2019-05-09	Compass Therapeutics Llc	Cd137 antibodies and pd-1 antagonists and uses thereof
TW201922294A (zh)	2017-10-31	2019-06-16	美商伊繆諾金公司	抗體-藥物結合物與阿糖胞苷之組合治療
JP2021502349A (ja)	2017-11-06	2021-01-28	ヤンセンバイオテツク，インコーポレーテツド	抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
WO2019094595A2 (en)	2017-11-09	2019-05-16	Pinteon Therapeutics Inc.	Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
BR112020008888A2 (pt)	2017-11-16	2020-10-20	Novartis Ag	terapias de combinação
EP3713961A2 (de)	2017-11-20	2020-09-30	Compass Therapeutics LLC	Cd137-antikörper und tumorantigenbindende antikörper sowie deren verwendung
MX2020005473A (es)	2017-11-27	2020-08-27	Purdue Pharma Lp	Anticuerpos humanizados que se dirigen al factor tisular humano.
EP3720881A1 (de)	2017-12-08	2020-10-14	Elstar Therapeutics, Inc.	Multispezifische moleküle und verwendungen davon
BR112020010085A2 (pt)	2017-12-09	2020-10-13	Abbott Laboratories	métodos para auxiliar no diagnóstico e avaliar uma lesão cerebral traumática em um indivíduo humano usando uma combinação de gfap e uch-l1
AU2018378971B9 (en)	2017-12-09	2025-04-17	Abbott Laboratories	Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1)
US12406749B2 (en)	2017-12-15	2025-09-02	The Broad Institute, Inc.	Systems and methods for predicting repair outcomes in genetic engineering
US12247060B2 (en)	2018-01-09	2025-03-11	Marengo Therapeutics, Inc.	Calreticulin binding constructs and engineered T cells for the treatment of diseases
CN111868082A (zh)	2018-02-02	2020-10-30	博奥泰克尼公司	调节vista和vsig3的相互作用的化合物及其制备和使用方法
WO2019150309A1 (en)	2018-02-02	2019-08-08	Hammack Scott	Modulators of gpr68 and uses thereof for treating and preventing diseases
GB201802486D0 (en)	2018-02-15	2018-04-04	Ucb Biopharma Sprl	Methods
SG11202007821WA (en)	2018-02-21	2020-09-29	Five Prime Therapeutics Inc	B7-h4 antibody formulations
US20210032334A1 (en)	2018-02-28	2021-02-04	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
KR20200144094A (ko)	2018-03-02	2020-12-28	파이브 프라임 테라퓨틱스, 인크.	B7-h4 항체 및 이의 사용 방법
CA3092551A1 (en)	2018-03-05	2019-09-12	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
JP2021517461A (ja)	2018-03-12	2021-07-26	ゾエティス・サービシーズ・エルエルシー	抗ｎｇｆ抗体およびその方法
CN112566642B (zh)	2018-03-14	2025-01-17	纪念斯隆凯特琳癌症中心	抗聚唾液酸抗体及其用途
US12152073B2 (en)	2018-03-14	2024-11-26	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to calreticulin and uses thereof
WO2019178364A2 (en)	2018-03-14	2019-09-19	Elstar Therapeutics, Inc.	Multifunctional molecules and uses thereof
WO2019178269A2 (en)	2018-03-14	2019-09-19	Surface Oncology, Inc.	Antibodies that bind cd39 and uses thereof
EP3768317A4 (de)	2018-03-22	2021-12-22	Surface Oncology, Inc.	Anti-il-27-antikörper und verwendungen davon
WO2019180272A1 (en)	2018-03-23	2019-09-26	Fundación Instituto De Investigación Sanitaria De Santiago De Compostela	Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
LT3775909T (lt)	2018-03-26	2023-08-10	Glycanostics S.R.O.	Priemonės ir būdai, skirti baltymo glikozilinimo profilio nustatymui
WO2019195126A1 (en)	2018-04-02	2019-10-10	Bristol-Myers Squibb Company	Anti-trem-1 antibodies and uses thereof
US12103972B2 (en)	2018-04-06	2024-10-01	Dana-Farber Cancer Institute, Inc.	KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
WO2019200357A1 (en)	2018-04-12	2019-10-17	Surface Oncology, Inc.	Biomarker for cd47 targeting therapeutics and uses therefor
US20210147547A1 (en)	2018-04-13	2021-05-20	Novartis Ag	Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
US20210230255A1 (en)	2018-04-27	2021-07-29	Fondazione Ebri Rita Levi-Montalcini	Antibody directed against a tau-derived neurotoxic peptide and uses thereof
AU2019265888A1 (en)	2018-05-10	2020-11-26	Neuracle Science Co., Ltd.	Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
TW202003048A (zh)	2018-05-15	2020-01-16	美商伊繆諾金公司	用抗體-藥物偶聯物及flt3抑制劑之組合治療
EP3797120A1 (de)	2018-05-21	2021-03-31	Compass Therapeutics LLC	Zusammensetzungen und verfahren zur steigerung der abtötung von zielzellen durch nk-zellen
WO2019226658A1 (en)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Multispecific antigen-binding compositions and methods of use
US12157760B2 (en)	2018-05-23	2024-12-03	The Broad Institute, Inc.	Base editors and uses thereof
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US11913044B2 (en)	2018-06-14	2024-02-27	President And Fellows Of Harvard College	Evolution of cytidine deaminases
SG11202012312UA (en)	2018-06-18	2021-01-28	UCB Biopharma SRL	Gremlin-1 antagonist for the prevention and treatment of cancer
SG11202012712YA (en)	2018-06-19	2021-01-28	Atarga Llc	Antibody molecules to complement component 5 and uses thereof
WO2019244107A1 (en)	2018-06-21	2019-12-26	Daiichi Sankyo Company, Limited	Compositions including cd3 antigen binding fragments and uses thereof
EP3814376B1 (de)	2018-06-26	2025-09-03	Mor Research Applications Ltd.	Transthyretinantikörper und verwendungen davon
AU2019297451A1 (en)	2018-07-03	2021-01-28	Marengo Therapeutics, Inc.	Anti-TCR antibody molecules and uses thereof
WO2020008083A1 (es)	2018-07-05	2020-01-09	Consejo Superior De Investigaciones Científicas	Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
EP3820495A4 (de)	2018-07-09	2022-07-20	The Broad Institute Inc.	Rna-programmierbare epigenetische rna-modifikatoren und deren verwendungen
EP3820896A1 (de)	2018-07-11	2021-05-19	Scholar Rock, Inc.	Tgfbeta1-inhibitoren und verwendung davon
TW202005981A (zh)	2018-07-11	2020-02-01	美商供石公司	高親和性、異構體選擇性之TGFβ1抑制劑及其用途
EP3677278B1 (de)	2018-07-11	2021-11-10	Scholar Rock, Inc.	Isoformselektive tgfbeta1-inhibitoren und deren verwendung
US20200025776A1 (en)	2018-07-18	2020-01-23	Janssen Biotech, Inc.	Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
IL280199B2 (en)	2018-07-20	2025-08-01	Pf Medicament	Receptor for vista
WO2020021465A1 (en)	2018-07-25	2020-01-30	Advanced Accelerator Applications (Italy) S.R.L.	Method of treatment of neuroendocrine tumors
SI4177356T1 (sl)	2018-08-08	2025-04-30	Pml Screening, Llc	Postopki za ocenjevanje tveganja za razvoj virusne bolezni z genetskim testom
EP3833443A1 (de)	2018-08-09	2021-06-16	Compass Therapeutics LLC	Antigenbindende mittel, die cd277 binden, und verwendungen davon
US12460004B2 (en)	2018-08-09	2025-11-04	Compass Therapeutics Llc	Antibodies that bind CD277 and uses thereof
WO2020033925A2 (en)	2018-08-09	2020-02-13	Compass Therapeutics Llc	Antibodies that bind cd277 and uses thereof
WO2020037215A1 (en)	2018-08-17	2020-02-20	Icahn School Of Medicine At Mount Sinai	Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
US11492645B2 (en) *	2018-08-29	2022-11-08	Shanghaitech University	Composition and use of Cas protein inhibitors
JP7617634B2 (ja)	2018-09-14	2025-01-20	プレリュードコーポレーション	浸潤性乳癌のリスクを有する対象の治療の選択方法
FI3883606T3 (fi)	2018-09-24	2023-09-07	Janssen Biotech Inc	Turvallinen ja tehokas menetelmä haavaisen paksusuolitulehduksen hoitamiseksi anti-il12/il23-vasta-aineella
AU2019346645A1 (en)	2018-09-27	2021-04-29	Marengo Therapeutics, Inc.	CSF1R/CCR2 multispecific antibodies
TW202019958A (zh)	2018-09-28	2020-06-01	日商協和麒麟股份有限公司	Il-36抗體及其用途
WO2020070678A2 (en)	2018-10-03	2020-04-09	Staten Biotechnology B.V.	Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
IL281988B2 (en)	2018-10-05	2025-03-01	Bavarian Nordic As	Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
UY38407A (es)	2018-10-15	2020-05-29	Novartis Ag	Anticuerpos estabilizadores de trem2
US12297262B2 (en)	2018-10-23	2025-05-13	Scholar Rock, Inc.	RGMC-selective inhibitors and use thereof
GB201817311D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
GB201817309D0 (en)	2018-10-24	2018-12-05	Ucb Biopharma Sprl	Antibodies
WO2020086408A1 (en)	2018-10-26	2020-04-30	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	A high-yield perfusion-based transient gene expression bioprocess
WO2020092453A1 (en)	2018-10-29	2020-05-07	The Broad Institute, Inc.	Nucleobase editors comprising geocas9 and uses thereof
WO2020102387A1 (en)	2018-11-13	2020-05-22	Compass Therapeutics Llc	Multispecific binding constructs against checkpoint molecules and uses thereof
JP2022513082A (ja)	2018-11-19	2022-02-07	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	免疫応答を調節するためのＩＲＥ１α－ＸＢＰ１シグナル伝達経路バイオマーカーの使用
MX2021005560A (es)	2018-11-20	2021-06-23	Bavarian Nordic As	Terapia para el tratamiento del cancer con administracion intratumoral y/o intravenosa de un virus vaccinia ankara (mva) recombinante que codifica ligando 4-1bbl (cd137l) y/o ligando del cumulo o grupo de diferenciacion 40 (cd40l).
CA3120237A1 (en)	2018-11-20	2020-05-28	Janssen Biotech, Inc.	Safe and effective method of treating psoriasis with anti-il-23 specific antibody
SG11202105161YA (en)	2018-12-13	2021-06-29	Surface Oncology Inc	Anti-il-27 antibodies and uses thereof
EP3897722A4 (de)	2018-12-18	2022-09-14	Janssen Biotech, Inc.	Sichere und wirksame methode zur behandlung von lupus mit anti-il12/il23-antikörper
AU2019402163A1 (en)	2018-12-20	2021-07-08	Kyowa Kirin Co., Ltd.	Fn14 antibodies and uses thereof
KR20210106483A (ko)	2018-12-20	2021-08-30	노파르티스 아게	Mdm2 억제제를 위한 확장된 저용량 요법
WO2020135559A1 (en)	2018-12-26	2020-07-02	Nanjing Legend Biotech Co., Ltd.	Cd30-binding moieties, chimeric antigen receptors, and uses thereof
US12492244B2 (en)	2019-01-02	2025-12-09	Neuracle Science Co., Ltd.	Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2020148651A1 (en)	2019-01-15	2020-07-23	Janssen Biotech, Inc.	Anti-tnf antibody compositions and methods for the treatment of juvenile idiopathic arthritis
BR112021013571A2 (pt)	2019-01-16	2021-09-21	Compass Therapeutics Llc	Formulações de anticorpos que se ligam a cd137 humano e usos das mesmas
GB201900732D0 (en)	2019-01-18	2019-03-06	Ucb Biopharma Sprl	Antibodies
US12351837B2 (en)	2019-01-23	2025-07-08	The Broad Institute, Inc.	Supernegatively charged proteins and uses thereof
EP4434541A3 (de)	2019-01-23	2025-02-26	New York University	Für die delta-1-kette des t-zell-rezeptors spezifische antikörper
IL284794B2 (en)	2019-01-23	2025-10-01	Janssen Biotech Inc	Anti-TNF antibody preparations for use in methods of treating psoriatic arthritis
KR20210121174A (ko)	2019-01-30	2021-10-07	스칼러 락, 인크.	TGFβ의 LTBP 복합체-특이적 억제제 및 그의 용도
US11738050B2 (en)	2019-02-01	2023-08-29	Regents Of The University Of Minnesota	Compounds binding to fibroblast activation protein alpha
EP3693063A1 (de)	2019-02-06	2020-08-12	Diaccurate	Verfahren und zusammensetzungen zur behandlung von krebs
EP3696191A1 (de)	2019-02-14	2020-08-19	Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC)	Car-t-zellen zur behandlung von cd1a-positivem krebs
US10871640B2 (en)	2019-02-15	2020-12-22	Perkinelmer Cellular Technologies Germany Gmbh	Methods and systems for automated imaging of three-dimensional objects
SG11202109061YA (en)	2019-02-21	2021-09-29	Marengo Therapeutics Inc	Multifunctional molecules that bind to t cell related cancer cells and uses thereof
AU2020224680B2 (en)	2019-02-21	2025-06-19	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
AU2020224681A1 (en)	2019-02-21	2021-09-16	Marengo Therapeutics, Inc.	Antibody molecules that bind to NKp30 and uses thereof
GB2598218B (en)	2019-02-21	2024-05-08	Marengo Therapeutics Inc	Anti-TCR antibody molecules and uses thereof
EP3927746A1 (de)	2019-02-21	2021-12-29	Marengo Therapeutics, Inc.	An calreticulin bindende multifunktionsmoleküle und ihre verwendungen
PL3930847T3 (pl)	2019-02-26	2024-07-08	Inspirna, Inc.	Przeciwciała anty-mertk o wysokim powinowactwie i ich zastosowania
WO2020185763A1 (en)	2019-03-11	2020-09-17	Memorial Sloan Kettering Cancer Center	Cd22 antibodies and methods of using the same
CN113825769A (zh)	2019-03-14	2021-12-21	詹森生物科技公司	用于产生抗tnf抗体组合物的方法
KR20210141998A (ko)	2019-03-14	2021-11-23	얀센 바이오테크 인코포레이티드	항-tnf 항체 조성물의 제조 방법
WO2020183418A1 (en)	2019-03-14	2020-09-17	Janssen Biotech, Inc.	Manufacturing methods for producing anti-il12/il23 antibody compositions
CN113840838A (zh)	2019-03-14	2021-12-24	詹森生物科技公司	用于产生抗tnf抗体组合物的制造方法
MA55383A (fr)	2019-03-18	2022-01-26	Janssen Biotech Inc	Méthode de traitement du psoriasis chez des sujets pédiatriques avec un anticorps anti-il12/il23
AU2020242032A1 (en)	2019-03-19	2021-10-07	Massachusetts Institute Of Technology	Methods and compositions for editing nucleotide sequences
CN113874392B (zh)	2019-03-28	2025-10-21	丹尼斯科美国公司	工程化抗体
JP2022527790A (ja)	2019-03-29	2022-06-06	アターガ，エルエルシー	抗ｆｇｆ２３抗体分子
US12473543B2 (en)	2019-04-17	2025-11-18	The Broad Institute, Inc.	Adenine base editors with reduced off-target effects
US20220289854A1 (en)	2019-04-30	2022-09-15	Dana-Farber Cancer Institute, Inc.	Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
MX2021014302A (es)	2019-05-23	2022-01-04	Janssen Biotech Inc	Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
CA3142665A1 (en)	2019-06-03	2020-12-10	Janssen Biotech, Inc.	Anti-tnf antibody compositions, and methods for the treatment of psoriatic arthritis
MA56026A (fr)	2019-06-03	2022-04-06	Janssen Biotech Inc	Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
WO2020245766A1 (en)	2019-06-04	2020-12-10	Janssen Biotech, Inc.	Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
TW202112822A (zh)	2019-06-17	2021-04-01	美商威特拉公司	針對cd138之人類化抗體分子及其用途
EP4004025A1 (de)	2019-07-26	2022-06-01	Visterra, Inc.	Interleukin-2-wirkstoffe und verwendungen davon
FI4007777T3 (fi)	2019-08-02	2024-01-11	Fundacio De Recerca Clinic Barcelona Inst Dinvestigacions Biomediques August Pi I Sunyer Frcb Idibap	CAR-T-soluja B-solujen kypsymisantigeeniä (BCMA) vastaan multippelin myelooman hoitoon
EP4031658A1 (de)	2019-08-07	2022-07-27	DB Biotech, AS	Verbesserte meerrettichperoxidase-polypeptide
MX2022001882A (es)	2019-08-12	2022-05-30	Aptevo Res & Development Llc	Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.
WO2021028752A1 (en)	2019-08-15	2021-02-18	Janssen Biotech, Inc.	Anti-tfn antibodies for treating type i diabetes
WO2021042019A1 (en)	2019-08-30	2021-03-04	Agenus Inc.	Anti-cd96 antibodies and methods of use thereof
WO2021044014A1 (en)	2019-09-04	2021-03-11	Y-Biologics Inc.	Anti-vsig4 antibody or antigen binding fragment and uses thereof
US20220332799A1 (en)	2019-09-04	2022-10-20	Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne)	Herv inhibitors for use in treating tauopathies
CN114450024A (zh)	2019-09-16	2022-05-06	表面肿瘤学公司	抗cd39抗体组合物和方法
CN114502590A (zh)	2019-09-18	2022-05-13	诺华股份有限公司	Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
TW202124446A (zh)	2019-09-18	2021-07-01	瑞士商諾華公司	與ｅｎｔｐｄ２抗體之組合療法
MX2022003719A (es)	2019-09-25	2022-04-26	Surface Oncology Inc	Anticuerpos anti-il-27 y sus usos.
KR20220088428A (ko)	2019-09-26	2022-06-27	주식회사 에스티큐브앤컴퍼니	글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법
CN114829404B (zh)	2019-10-09	2025-09-09	斯特库比公司	对糖基化的lag3特异的抗体及其使用方法
US12435330B2 (en)	2019-10-10	2025-10-07	The Broad Institute, Inc.	Methods and compositions for prime editing RNA
US11781138B2 (en)	2019-10-14	2023-10-10	Aro Biotherapeutics Company	FN3 domain-siRNA conjugates and uses thereof
WO2021076543A1 (en)	2019-10-14	2021-04-22	Aro Biotherapeutics Company	Epcam binding fibronectin type iii domains
EP4045061A4 (de)	2019-10-14	2024-04-17	ARO Biotherapeutics Company	Cd71-bindende fibronectin-typ iii-domänen
MX2022004766A (es)	2019-10-21	2022-05-16	Novartis Ag	Terapias combinadas con venetoclax e inhibidores de tim-3.
JP2022553306A (ja)	2019-10-21	2022-12-22	ノバルティスアーゲー	Ｔｉｍ－３阻害剤およびその使用
US11459389B2 (en)	2019-10-24	2022-10-04	Massachusetts Institute Of Technology	Monoclonal antibodies that bind human CD161
KR20220106775A (ko)	2019-11-20	2022-07-29	버베리안 노딕 에이/에스	암 치료를 위한 종양내 및/또는 정맥내 투여를 위한 재조합 mva 바이러스
GB201917480D0 (en)	2019-11-29	2020-01-15	Univ Oxford Innovation Ltd	Antibodies
GB201919058D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibodies
EP4076660A1 (de)	2019-12-20	2022-10-26	Novartis AG	Verwendung von anti-tgf-beta-antikörpern und checkpoint-inhibitoren zur behandlung von proliferativen erkrankungen
GB201919061D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Multi-specific antibody
GB201919062D0 (en)	2019-12-20	2020-02-05	Ucb Biopharma Sprl	Antibody
TWI877278B (zh)	2019-12-30	2025-03-21	美商思進公司	以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
EP4084821A4 (de)	2020-01-03	2024-04-24	Marengo Therapeutics, Inc.	An cd33 bindende multifunktionsmoleküle und ihre verwendungen
EP4084823A4 (de)	2020-01-03	2024-05-15	Marengo Therapeutics, Inc.	Anti-tcr-antikörpermoleküle und ihre verwendungen
US11859000B2 (en)	2020-01-06	2024-01-02	Vaccinex Inc.	Anti-CCR8 antibodies and uses thereof
KR20220139888A (ko)	2020-01-11	2022-10-17	스칼러 락, 인크.	TGFβ 억제제 및 그의 용도
CA3166328A1 (en)	2020-01-11	2021-07-15	Scholar Rock, Inc.	Tgf-beta inhibitors and use thereof
TWI869528B (zh)	2020-01-13	2025-01-11	美商威特拉公司	C5ar1抗體分子及其用途
TW202140037A (zh)	2020-01-17	2021-11-01	瑞士商諾華公司	組合療法
US20230075965A1 (en)	2020-01-24	2023-03-09	Constantine S. Mitsiades	Uses of biomarkers for improving immunotherapy
EP4100435A1 (de)	2020-02-05	2022-12-14	Larimar Therapeutics, Inc.	Tat-peptidbindende proteine und ihre verwendungen
ES2975410T3 (es)	2020-02-13	2024-07-05	UCB Biopharma SRL	Anticuerpos biespecíficos que se unen a HVEM y CD9
US20230151109A1 (en)	2020-02-13	2023-05-18	UCB Biopharma SRL	Bispecific antibodies against cd9
US20230151108A1 (en)	2020-02-13	2023-05-18	UCB Biopharma SRL	Bispecific antibodies against cd9 and cd137
WO2021160267A1 (en)	2020-02-13	2021-08-19	UCB Biopharma SRL	Bispecific antibodies against cd9 and cd7
US20230125234A1 (en)	2020-02-13	2023-04-27	UCB Biopharma SRL	Anti cd44-ctla4 bispecific antibodies
EP4106788A1 (de)	2020-02-18	2022-12-28	Alector LLC	Pilra-antikörper und verfahren zur verwendung davon
KR20220151195A (ko)	2020-03-06	2022-11-14	오엔에이 테라퓨틱스 에스.엘.	항-cd36 항체 및 암을 치료하기 위한 이의 용도
US11896619B2 (en)	2020-03-10	2024-02-13	Massachusetts Institute Of Technology	Compositions and methods for immunotherapy of NPM1c-positive cancer
AU2021233158A1 (en)	2020-03-11	2022-09-29	Fundació Institut D'investigació En Ciències De La Salut Germans Trias I Pujol (Igtp)	CD22 targeting-moiety for the treatment of B-cell acute lymphoblastic leukemia (B-ALL)
UY39135A (es)	2020-03-26	2021-10-29	Univ Vanderbilt	ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
WO2021202473A2 (en)	2020-03-30	2021-10-07	Danisco Us Inc	Engineered antibodies
EP4126064A1 (de)	2020-04-03	2023-02-08	Visterra, Inc.	Antikörpermolekül-wirkstoff-konjugate und verwendungen davon
CA3175523A1 (en)	2020-04-13	2021-10-21	Antti Virtanen	Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
WO2021217085A1 (en)	2020-04-24	2021-10-28	Marengo Therapeutics, Inc.	Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2021220215A1 (en)	2020-05-01	2021-11-04	Novartis Ag	Engineered immunoglobulins
WO2021220218A1 (en)	2020-05-01	2021-11-04	Novartis Ag	Immunoglobulin variants
BR112022022378A2 (pt)	2020-05-05	2022-12-13	Janssen Biotech Inc	Métodos para tratamento da doença de crohn com anticorpo específico anti-il23
JP2023525304A (ja)	2020-05-08	2023-06-15	ザブロードインスティテュート，インコーポレーテッド	標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
KR20230012539A (ko)	2020-05-13	2023-01-26	디스크 메디슨, 인크.	골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
JP2023528235A (ja)	2020-05-17	2023-07-04	アストラゼネカ・ユーケイ・リミテッド	ＳＡＲＳ－ＣｏＶ－２抗体、並びにこれを選択及び使用する方法
WO2021234634A1 (en)	2020-05-21	2021-11-25	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2021239666A1 (en)	2020-05-26	2021-12-02	Diaccurate	Therapeutic methods
CN115803062B (zh)	2020-06-03	2025-09-09	博泰康医药公司	滋养层细胞表面抗原2(trop-2)抗体
MX2022016591A (es)	2020-06-24	2023-04-20	Visterra Inc	Moléculas de anticuerpo contra april y usos de las mismas.
CN116390772A (zh)	2020-07-07	2023-07-04	博泰康医药公司	新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
CA3189402A1 (en)	2020-07-13	2022-01-20	Janssen Biotech, Inc.	Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
AU2021313348A1 (en)	2020-07-20	2023-03-09	Astrazeneca Uk Limited	SARS-CoV-2 proteins, anti-SARS-CoV-2 antibodies, and methods of using the same
WO2022026592A2 (en)	2020-07-28	2022-02-03	Celltas Bio, Inc.	Antibody molecules to coronavirus and uses thereof
US20220073603A1 (en)	2020-07-30	2022-03-10	Janssen Biotech, Inc.	Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
KR20230042301A (ko)	2020-08-04	2023-03-28	애벗트 라보라토리이즈	샘플에서 sars-cov-2 단백질을 검출하기 위한 개선된 방법 및 키트
SI4200018T1 (sl)	2020-08-18	2025-07-31	Cephalon Llc	Protitelesa proti-PAR-2 in postopki njihove uporabe
CA3190755A1 (en)	2020-08-26	2022-03-03	Andreas Loew	Multifunctional molecules that bind to calreticulin and uses thereof
WO2022046922A2 (en)	2020-08-26	2022-03-03	Marengo Therapeutics, Inc.	Antibody molecules that bind to nkp30 and uses thereof
EP4204458A4 (de)	2020-08-26	2024-10-09	Marengo Therapeutics, Inc.	Verfahren zum nachweis von trbc1 oder trbc2
US20230338587A1 (en)	2020-08-31	2023-10-26	Advanced Accelerator Applications International Sa	Method of treating psma-expressing cancers
EP4204021A1 (de)	2020-08-31	2023-07-05	Advanced Accelerator Applications International S.A.	Verfahren zur behandlung von psma-exprimierenden krebsarten
EP4228764A1 (de)	2020-10-14	2023-08-23	Five Prime Therapeutics, Inc.	Anti-c-chemokinrezeptor-8-(ccr8)-antikörper und verfahren zur verwendung davon
US20230382978A1 (en)	2020-10-15	2023-11-30	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
EP4229086A1 (de)	2020-10-15	2023-08-23	UCB Biopharma SRL	Bindungsmoleküle, die cd45 multimerisieren
WO2022087274A1 (en)	2020-10-21	2022-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibodies that neutralize type-i interferon (ifn) activity
WO2022087426A1 (en)	2020-10-23	2022-04-28	Hq Han	Bifunctional antagonists of activin and tumor necrosis factor-alpha and uses thereof
US20230408517A1 (en)	2020-11-24	2023-12-21	Bio-Techne Corporation	Anti-severe acute respiratory syndrome coronavirus antibodies
US20220170948A1 (en)	2020-12-01	2022-06-02	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
WO2023102384A1 (en)	2021-11-30	2023-06-08	Abbott Laboratories	Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
IL303328A (en)	2020-12-01	2023-07-01	Aptevo Res & Development Llc	Heterodimeric psma and cd3-binding bispecific antibodies
TW202237171A (zh)	2020-12-04	2022-10-01	美商威特拉公司	使用介白素-2藥劑之方法
CN117043181A (zh)	2020-12-18	2023-11-10	基尼科萨制药有限公司	蛋白质组合物以及其产生和使用方法
EP4271998A1 (de)	2020-12-30	2023-11-08	Abbott Laboratories	Verfahren zur bestimmung des sars-cov-2-antigens und anti-sars-cov-2-antikörpers in einer probe
CA3202832A1 (en)	2020-12-31	2022-07-07	Romesh R. Subramanian	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP4277665A1 (de)	2021-01-13	2023-11-22	Memorial Sloan Kettering Cancer Center	Anti-dll3-antikörper-wirkstoff-konjugat
US20240115720A1 (en)	2021-01-13	2024-04-11	Memorial Sloan Kettering Cancer Center	Antibody-pyrrolobenzodiazepine derivative conjugate
AU2022211021A1 (en)	2021-01-20	2023-08-03	Visterra, Inc.	Interleukin-2 mutants and uses thereof
WO2022162569A1 (en)	2021-01-29	2022-08-04	Novartis Ag	Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
US20240230671A9 (en)	2021-02-24	2024-07-11	Alladapt Immunotherapeutics, Inc.	Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
CA3211983A1 (en)	2021-03-03	2022-09-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	La protien as a novel regulator of osteoclastogenesis
US20240158503A1 (en)	2021-03-03	2024-05-16	Pierre Fabre Medicament	Anti-vsig4 antibody or antigen binding fragment and uses thereof
AU2022232007A1 (en)	2021-03-12	2023-10-26	Janssen Biotech, Inc.	Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
CA3212729A1 (en)	2021-03-12	2022-09-15	Janssen Biotech, Inc.	Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
CN117321418A (zh)	2021-03-18	2023-12-29	诺华股份有限公司	癌症生物标志物及其使用方法
WO2022204581A2 (en)	2021-03-26	2022-09-29	Scholar Rock, Inc.	Tgf-beta inhibitors and use thereof
EP4067381A1 (de)	2021-04-01	2022-10-05	Julius-Maximilians-Universität Würzburg	Neue tnfr2-bindende moleküle
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
BR112023020832A2 (pt)	2021-04-08	2023-12-19	Marengo Therapeutics Inc	Moléculas multifuncionais ligadas a tcr e seus usos
US12239710B2 (en)	2021-04-14	2025-03-04	Aro Biotherapeutics Company	FN3 domain-siRNA conjugates and uses thereof
MX2023012128A (es)	2021-04-14	2024-01-11	Aro Biotherapeutics Company	Dominios tipo iii de la fibronectina que se unen a cd71.
US12472248B2 (en)	2021-04-29	2025-11-18	The Government Of The United States, As Represented By The Secretary Of The Army	Antibodies against fentanyl and fentanyl analogs
AU2022270170A1 (en)	2021-05-07	2023-09-21	Surface Oncology, LLC	Anti-il-27 antibodies and uses thereof
BR112023024169A2 (pt)	2021-05-18	2024-02-06	Abbott Lab	Métodos para avaliar lesão cerebral em um indivíduo pediátrico
WO2022251446A1 (en)	2021-05-28	2022-12-01	Alexion Pharmaceuticals, Inc.	Methods for detecting cm-tma biomarkers
EP4348260A2 (de)	2021-06-03	2024-04-10	Scholar Rock, Inc.	Tgf-beta inhibitoren und deren therapeutische verwendung
CA3218590A1 (en)	2021-06-07	2022-12-15	Providence Health & Services - Oregon	Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
US20240280561A1 (en)	2021-06-08	2024-08-22	Dana-Farber Cancer Institute, Inc.	Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2022263357A1 (en)	2021-06-14	2022-12-22	Argenx Iip Bv	Anti-il-9 antibodies and methods of use thereof
EP4528280A3 (de)	2021-06-14	2025-07-02	Abbott Laboratories	Verfahren zur diagnose oder unterstützung der diagnose von hirnverletzungen durch akustische energie, elektromagnetische energie, überdruckwelle und/oder explosionswind
CA3221555A1 (en)	2021-06-23	2022-12-29	Kimberly LONG	A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders
IL309405A (en)	2021-06-29	2024-02-01	Seagen Inc	Methods for treating cancer with a combination of non-fucosylated anti-CD70 antibody and CD47 antagonist
IL309996A (en)	2021-07-09	2024-03-01	Janssen Biotech Inc	Production methods for the production of anti-TNF antibody compositions
US20230040065A1 (en)	2021-07-09	2023-02-09	Janssen Biotech, Inc.	Manufacturing Methods for Producing Anti-TNF Antibody Compositions
EP4367138A1 (de)	2021-07-09	2024-05-15	Janssen Biotech, Inc.	Herstellungsverfahren zur herstellung von anti-il12/il23-antikörperzusammensetzungen
WO2023285878A1 (en)	2021-07-13	2023-01-19	Aviation-Ophthalmology	Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
US20240342215A1 (en)	2021-07-14	2024-10-17	Regeneron Pharmaceuticals, Inc.	Engineered t cell receptors fused to binding domains from antibodies
KR20240042476A (ko)	2021-07-30	2024-04-02	오엔에이 테라퓨틱스 에스.엘.	항-cd36 항체 및 암을 치료하기 위한 이의 용도
EP4384545A1 (de)	2021-08-10	2024-06-19	BYOMass Inc.	Anti-gdf15-antikörper, zusammensetzungen und verwendungen davon
EP4392780A1 (de)	2021-08-26	2024-07-03	Glycanostics s.r.o.	Glykoproteinbiomarker zur diagnose von krebs
JP2024534849A (ja)	2021-08-31	2024-09-26	アボット・ラボラトリーズ	脳の損傷を診断する方法及びシステム
CN118715440A (zh)	2021-08-31	2024-09-27	雅培实验室	诊断脑损伤的方法和系统
WO2023039243A2 (en) *	2021-09-13	2023-03-16	Achelois Biopharma, Inc.	Hepatitis b virus antivirus (hbv-antivirus) compositions and methods of use
CA3231890A1 (en)	2021-09-14	2023-03-23	Jan Tkac	Use of lectins to determine mammaglobin-a glycoforms in breast cancer
CA3232420A1 (en)	2021-09-20	2023-03-23	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
US20250223376A1 (en)	2021-09-20	2025-07-10	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
CA3232176A1 (en)	2021-09-30	2023-04-06	Beth MCQUISTON	Methods and systems of diagnosing brain injury
CA3235627A1 (en)	2021-10-18	2023-04-27	Byomass Inc.	Anti-activin a antibodies, compositions and uses thereof
CA3236779A1 (en)	2021-10-29	2023-05-04	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
EP4177266A1 (de)	2021-11-05	2023-05-10	Katholieke Universiteit Leuven	Neutralisierende humane anti-sars-cov-2-antikörper
CA3238377A1 (en)	2021-11-15	2023-05-19	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
US20250034559A1 (en)	2021-11-17	2025-01-30	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
US20230159633A1 (en)	2021-11-23	2023-05-25	Janssen Biotech, Inc.	Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
US20230348614A1 (en)	2021-11-24	2023-11-02	Visterra, Inc.	Engineered antibody molecules to cd138 and uses thereof
US20250381241A1 (en)	2021-11-29	2025-12-18	Dana-Farber Cancer Institute, Inc.	Methods and compositions to modulate riok2
US20240041981A1 (en)	2021-12-01	2024-02-08	Visterra, Inc.	Methods of using interleukin-2 agents
CA3240822A1 (en)	2021-12-17	2023-06-22	Tony Lee	Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
EP4452316A1 (de)	2021-12-22	2024-10-30	BYOMass Inc.	Abzielung auf den gdf15-gfral-signalweg
WO2023118508A1 (en)	2021-12-23	2023-06-29	Bavarian Nordic A/S	Recombinant mva viruses for intraperitoneal administration for treating cancer
WO2023147107A1 (en)	2022-01-31	2023-08-03	Byomass Inc.	Myeloproliferative conditions
WO2023150652A1 (en)	2022-02-04	2023-08-10	Abbott Laboratories	Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
TW202342548A (zh)	2022-02-07	2023-11-01	美商威特拉公司	抗獨特型(anti-idiotype)抗體分子及其用途
TW202342510A (zh)	2022-02-18	2023-11-01	英商Ｒｑ生物科技有限公司	抗體
US20230312703A1 (en)	2022-03-30	2023-10-05	Janssen Biotech, Inc.	Method of Treating Psoriasis with IL-23 Specific Antibody
WO2023192436A1 (en)	2022-03-31	2023-10-05	Alexion Pharmaceuticals, Inc.	Singleplex or multiplexed assay for complement markers in fresh biological samples
GB202205200D0 (en)	2022-04-08	2022-05-25	Ucb Biopharma Sprl	Combination with chemotherapy
GB202205203D0 (en)	2022-04-08	2022-05-25	UCB Biopharma SRL	Combination with inhibitor
EP4514381A1 (de)	2022-04-25	2025-03-05	Visterra, Inc.	Antikörpermoleküle gegen april und verwendungen davon
CR20240528A (es)	2022-04-29	2025-04-04	Astrazeneca Uk Ltd	Anticuerpos contra el sars-cov-2 y métodos para utilizarlos
US20250295809A1 (en)	2022-05-13	2025-09-25	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of her2 positive cancer
US20230374122A1 (en)	2022-05-18	2023-11-23	Janssen Biotech, Inc.	Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody
WO2023240124A1 (en)	2022-06-07	2023-12-14	Regeneron Pharmaceuticals, Inc.	Pseudotyped viral particles for targeting tcr-expressing cells
EP4296279A1 (de)	2022-06-23	2023-12-27	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Anti-transthyretin(ttr)-bindende proteine und ihre verwendungen
EP4548100A1 (de)	2022-06-29	2025-05-07	Abbott Laboratories	Magnetische pflegepunktsysteme und assays zur bestimmung von gfap in biologischen proben
CN119948051A (zh)	2022-07-15	2025-05-06	詹森生物科技公司	用于改善抗原结合可变区的生物工程化配对的材料和方法
EP4554619A1 (de)	2022-07-15	2025-05-21	Danisco US Inc.	Verfahren zur herstellung monoklonaler antikörper
EP4565597A2 (de)	2022-08-03	2025-06-11	Voyager Therapeutics, Inc.	Zusammensetzungen und verfahren zur durchquerung der blut-hirn-schranke
WO2024050354A1 (en)	2022-08-31	2024-03-07	Washington University	Alphavirus antigen binding antibodies and uses thereof
JP2025529210A (ja)	2022-09-01	2025-09-04	ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド	アポリポタンパク質ｌ１を導いて哺乳動物の細胞死を誘導するための組成物及び方法
JP2025529318A (ja)	2022-09-06	2025-09-04	アレクシオンファーマシューティカルズ，インコーポレイテッド	造血幹細胞移植関連血栓性微小血管症（ｈｓｃｔ－ｔｍａ）を有する患者における診断及び予後バイオマーカプロファイル
AU2023342055A1 (en)	2022-09-15	2025-03-13	Abbott Laboratories	Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
JP2025532716A (ja)	2022-09-21	2025-10-01	エルテラアーゲー	Ｌ１ｃａｍと結合する新規な結合分子
WO2024110898A1 (en)	2022-11-22	2024-05-30	Janssen Biotech, Inc.	Method of treating ulcerative colitis with anti-il23 specific antibody
WO2024138076A1 (en)	2022-12-22	2024-06-27	Scholar Rock, Inc.	Selective and potent inhibitory antibodies of myostatin activation
WO2024168061A2 (en)	2023-02-07	2024-08-15	Ayan Therapeutics Inc.	Antibody molecules binding to sars-cov-2
WO2024188356A1 (en)	2023-03-16	2024-09-19	Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd.	Ilt7-targeting antibodies and uses thereof
AU2024240009A1 (en)	2023-03-17	2025-09-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods for treatment of age-related macular degeneration
CN121399155A (zh)	2023-03-17	2026-01-23	奥西托普制药有限公司	抗磷酸胆碱抗体及其使用方法
WO2024194685A2 (en)	2023-03-17	2024-09-26	Oxitope Pharma B.V.	Anti-phosphocholine antibodies and methods of use thereof
WO2024211475A1 (en)	2023-04-04	2024-10-10	Abbott Laboratories	Use of biomarkers to determine whether a subject has sustained, may have sustained or is suspected of sustaining a subacute acquired brain injury (abi)
WO2024226969A1 (en)	2023-04-28	2024-10-31	Abbott Point Of Care Inc.	Improved assays, cartridges, and kits for detection of biomarkers, including brain injury biomarkers
AR132710A1 (es)	2023-05-19	2025-07-23	Servier Lab	Anticuerpos anti-met, adc, composiciones y usos de los mismos
AU2024277678A1 (en)	2023-05-25	2025-11-27	Dispatch Biotherapeutics, Inc.	Synthetic cancer antigens as targets for treating cancers
EP4484445A1 (de)	2023-06-26	2025-01-01	Universität zu Köln	Hcmv neutralisierende antikörper
WO2025068389A2 (en)	2023-09-27	2025-04-03	Elthera Ag	L1cam binding molecules for treating hematological malignancy diseases
US20250109187A1 (en)	2023-09-28	2025-04-03	Novavax, Inc.	ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
WO2025122634A1 (en)	2023-12-05	2025-06-12	Voyager Therapeutics, Inc.	Compositions and methods for the treatment of tau-related disorders
WO2025133707A1 (en)	2023-12-19	2025-06-26	Vectory Therapeutics B.V.	Anti-tdp-43 antibodies and uses thereof
US20260022185A1 (en)	2024-01-03	2026-01-22	Kiniksa Pharmaceuticals, Gmbh	Method of reducing aggregation in the virus-inactivated preparation of anti-cd40 antibodies
TW202540204A (zh)	2024-01-26	2025-10-16	西班牙商阿爾米雷爾有限公司	雙特異性分子及使用其的治療方法
GB202401567D0 (en)	2024-02-06	2024-03-20	St Georges Hospital Medical School	Treatment of infectious disease
WO2025171383A2 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens and related methods and uses
WO2025171388A1 (en)	2024-02-09	2025-08-14	Dispatch Biotherapeutics, Inc.	Engineered cancer antigens with modified domains and related methods and uses
US20250361297A1 (en)	2024-03-12	2025-11-27	Adaptam Therapeutics, S.L.	Anti- siglec-15 binding molecules and methods of use
CA3249015A1 (en)	2024-03-20	2025-10-31	Janssen Biotech, Inc.	Methods of treating crohn’s disease with anti-il23 specific antibody
WO2025226603A1 (en)	2024-04-22	2025-10-30	Surface Oncology, LLC	Methods for treating cancer using anti-ccr8 antibodies
WO2025235419A1 (en)	2024-05-06	2025-11-13	Generate Biomedicines, Inc.	Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
WO2025235420A1 (en)	2024-05-06	2025-11-13	Generate Biomedicines, Inc.	Methods of treating or preventing sarbecovirus with antibodies or antigen-binding fragments thereof
EP4650368A1 (de)	2024-05-13	2025-11-19	Epok Therapeutics Inc.	Tetravalente erythropoietinrezeptoragonisten
WO2026006472A2 (en)	2024-06-25	2026-01-02	Kiniksa Pharmaceuticals, Gmbh	Compositions of il-1r1 antibodies and methods of producing and using the same
WO2026003761A1 (en)	2024-06-27	2026-01-02	Janssen Biotech, Inc.	Methods of treating ulcerative colits with anti-il23 specific antibody
WO2026011013A1 (en)	2024-07-02	2026-01-08	Epibiologics, Inc.	Binding agents and uses thereof
WO2026027660A1 (en)	2024-08-02	2026-02-05	UCB Biopharma SRL	Formulations of anti-gremlin-1 antibodies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
WO1988006630A1 (en) *	1987-03-02	1988-09-07	Genex Corporation	Method for the preparation of binding molecules
US5223409A (en) *	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
ES2052027T5 (es) *	1988-11-11	2005-04-16	Medical Research Council	Clonacion de secuencias de dominio variable de inmunoglobulina.
CA2016841C (en) *	1989-05-16	1999-09-21	William D. Huse	A method for producing polymers having a preselected activity
AU627591B2 (en) *	1989-06-19	1992-08-27	Xoma Corporation	Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
CA2025398A1 (en)	1989-09-20	1992-03-15	Timothy Gerard Dinan	Diagnosis and treatment of a disorder of the gastrointestinal tract
US5427908A (en) *	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
DK0600866T3 (da) *	1990-06-01	1998-03-09	Chiron Corp	Præparater og fremgangsmåder til identifikation af biologisk aktive molekyler
US5723286A (en) *	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
US6172197B1 (en)	1991-07-10	2001-01-09	Medical Research Council	Methods for producing members of specific binding pairs
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
GB9019812D0 (en)	1990-09-11	1990-10-24	Scotgen Ltd	Novel antibodies for treatment and prevention of infection in animals and man
US5871974A (en) *	1990-09-28	1999-02-16	Ixsys Inc.	Surface expression libraries of heteromeric receptors
IL99552A0 (en) *	1990-09-28	1992-08-18	Ixsys Inc	Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9022190D0 (en) *	1990-10-12	1990-11-28	Perham Richard N	Immunogenic material
DE69129154T2 (de)	1990-12-03	1998-08-20	Genentech, Inc., South San Francisco, Calif.	Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
AU1457992A (en) *	1991-03-01	1992-10-06	Stratagene	Pcr generated dicistronic dna molecules for producing antibodies
ATE414768T1 (de) *	1991-04-10	2008-12-15	Scripps Research Inst	Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0663953B1 (de) *	1992-09-04	2001-12-05	The Scripps Research Institute	Phagemiden die einen oberflächenrezeptor und ein heterologes oberflächenprotein co-exprimieren

1992
- 1992-04-10 AT AT04076718T patent/ATE414768T1/de active
- 1992-04-10 JP JP51064992A patent/JP3672306B2/ja not_active Expired - Lifetime
- 1992-04-10 DK DK92910558T patent/DK0580737T3/da active
- 1992-04-10 AT AT92910558T patent/ATE269401T1/de active
- 1992-04-10 EP EP92910558A patent/EP0580737B1/de not_active Expired - Lifetime
- 1992-04-10 EP EP04076718A patent/EP1471142B1/de not_active Expired - Lifetime
- 1992-04-10 DE DE69233750T patent/DE69233750D1/de not_active Expired - Lifetime
- 1992-04-10 PT PT100379A patent/PT100379B/pt not_active IP Right Cessation
- 1992-04-10 US US08/133,011 patent/US5658727A/en not_active Expired - Lifetime
- 1992-04-10 WO PCT/US1992/003091 patent/WO1992018619A1/en not_active Ceased
- 1992-04-10 DK DK04076718T patent/DK1471142T3/da active
- 1992-04-10 ES ES04076718T patent/ES2315612T3/es not_active Expired - Lifetime
- 1992-04-10 DE DE69233367T patent/DE69233367T2/de not_active Expired - Lifetime
- 1992-04-10 AU AU17856/92A patent/AU662148B2/en not_active Expired
- 1992-04-10 CA CA 2108147 patent/CA2108147C/en not_active Expired - Lifetime
- 1992-04-10 ES ES92910558T patent/ES2223040T3/es not_active Expired - Lifetime
- 1992-04-10 IE IE116992A patent/IE921169A1/en not_active IP Right Cessation
1993
- 1993-10-08 NO NO19933610A patent/NO319371B1/no not_active IP Right Cessation
- 1993-10-08 FI FI934422A patent/FI120309B/fi not_active IP Right Cessation
1994
- 1994-10-12 US US08/322,730 patent/US5759817A/en not_active Expired - Lifetime
1997
- 1997-08-08 US US08/907,739 patent/US6235469B1/en not_active Expired - Fee Related
2000
- 2000-12-04 US US09/729,597 patent/US6468738B1/en not_active Expired - Fee Related
2002
- 2002-08-26 JP JP2002289257A patent/JP4108430B2/ja not_active Expired - Lifetime
- 2002-10-18 US US10/273,973 patent/US7118866B2/en not_active Expired - Fee Related
2005
- 2005-02-28 JP JP2005054302A patent/JP4118896B2/ja not_active Expired - Lifetime
- 2005-12-22 US US11/315,970 patent/US7985841B2/en not_active Expired - Fee Related
2007
- 2007-05-16 JP JP2007130665A patent/JP4118938B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JP4118938B2 (ja)	2008-07-16
CA2108147A1 (en)	1992-10-11
PT100379A (pt)	1993-08-31
AU662148B2 (en)	1995-08-24
AU1785692A (en)	1992-11-17
EP0580737A4 (en)	1996-04-24
US5658727A (en)	1997-08-19
CA2108147C (en)	2009-01-06
JP3672306B2 (ja)	2005-07-20
EP0580737B1 (de)	2004-06-16
WO1992018619A1 (en)	1992-10-29
US5759817A (en)	1998-06-02
NO933610D0 (no)	1993-10-08
EP0580737A1 (de)	1994-02-02
JP2007222179A (ja)	2007-09-06
US20040002057A1 (en)	2004-01-01
US20060257856A1 (en)	2006-11-16
JP4108430B2 (ja)	2008-06-25
JP2003204797A (ja)	2003-07-22
PT100379B (pt)	1999-01-29
US6468738B1 (en)	2002-10-22
US7985841B2 (en)	2011-07-26
NO319371B1 (no)	2005-07-25
JP2005218449A (ja)	2005-08-18
ES2315612T3 (es)	2009-04-01
DE69233367T2 (de)	2005-05-25
EP1471142B1 (de)	2008-11-19
IE921169A1 (en)	1992-10-21
JPH06506836A (ja)	1994-08-04
DK1471142T3 (da)	2009-03-09
ATE269401T1 (de)	2004-07-15
US6235469B1 (en)	2001-05-22
JP4118896B2 (ja)	2008-07-16
ES2223040T3 (es)	2005-02-16
DE69233750D1 (de)	2009-01-02
FI934422L (fi)	1993-12-08
EP1471142A1 (de)	2004-10-27
DK0580737T3 (da)	2004-11-01
US7118866B2 (en)	2006-10-10
DE69233367D1 (de)	2004-07-22
FI120309B (fi)	2009-09-15
FI934422A0 (fi)	1993-10-08
NO933610L (no)	1993-12-10

Publication	Publication Date	Title
ATE414768T1 (de)	2008-12-15	Bibliotheken heterodimerer rezeptoren mittels phagemiden
Miloux et al.	1997	Cloning of the human IL‐13Rα1 chain and reconstitution with the IL‐4Rα of a functional IL‐4/IL‐13 receptor complex
EP0615451B1 (de)	2005-12-07	Neue zytokine die cd30 binden
Lewis et al.	1992	Sequence of a second human KDEL receptor
WO1996018105A1 (en)	1996-06-13	Single chain t-cell receptor
Zeng et al.	2000	Cloning and characterization of a novel cDNA sequence encoding the precursor of a novel venom peptide (BmKbpp) related to a bradykinin‐potentiating peptide from Chinese scorpion Buthus martensii Karsch
EP3288582B1 (de)	2021-03-31	Nukleinsäurekonstrukt
KR960704038A (ko)	1996-08-31	세포 표면 수용체 Hek와 결합하는 사이토킨(Cytokines That Bind the Cell Surface Receptor Hek)
NZ515913A (en)	2004-01-30	Modified chimeric polypeptides with improved pharmacokinetic properties
WO2000018932A9 (en)	2000-08-31	Receptor based antagonists and methods of making and using
CA2420992A1 (en)	2001-10-18	Soluble zalpha11 cytokine receptors
CA2105534C (en)	2009-01-13	Tnf ligands
RU2000103824A (ru)	2001-12-10	Адипоцит-специфические белковые гомологи
Janknecht et al.	1992	Affinity purification of histidine-tagged proteins transiently produced in HeLa cells
AU632513B2 (en)	1993-01-07	Cdnas coding for the gamma subunit of the high-affinity receptor for immunoglobulin e
Ward et al.	2001	The rat interleukin 10 receptor: cloning and sequencing of cDNA coding for the alpha-chain protein sequence, and demonstration by western blotting of expression in the rat brain
Muto et al.	1995	High-Affinity Chimeric Human Granulocyte-Macrophage Colony-Stimulating Factor-Receptor Carrying the Cytoplasmic Domain of the β Subunit But Not the α Subunit Transduces Growth-Promoting Signals in Ba/F3 Cells
EP1612221A2 (de)	2006-01-04	Auf Rezeptorgrundlage arbeitende Screening-Verfahren für Protein Wechselwirkungen
AU2001281784A1 (en)	2002-02-21	Receptor-based interaction trap
Ueda et al.	2000	Cell-growth control by monomeric antigen: the cell surface expression of lysozyme-specific Ig V-domains fused to truncated Epo receptor
AU674523B2 (en)	1997-01-02	An interferon-alpha/beta binding protein its preparation and pharmaceutical compositions containing it
KR860006484A (ko)	1986-09-11	단백질 또는 당단백질의 제조방법
Pepin et al.	1996	Scanning-deletion analysis of the extracellular domain of the TGF-β receptor type II
Ito et al.	1992	Development of a prokaryotic expression vector that exploits dicistronic gene organization
Klaus	1988	Lymphocyte receptors, signals and cytokines a Newport Beach

Legal Events

Date	Code	Title	Description
2009-06-15	UEP	Publication of translation of european patent specification	Ref document number: 1471142 Country of ref document: EP

Date

Code

Title

Description

2009-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1471142

Country of ref document: EP